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A lEDlC/SBD Di\Y FOJU.i FOR LOCl~.L ?IIEi.U~.PY 
IH DWL·;CTED BURHS 
Abstract of Diss<~rtation 
Local burn therapy usually includes the application of medicated 
oint ments and dressings in order to lllinim.ize and eradicate infectioH . 
As this approach to l ocal therapy may present probleG".S r egardine 
application and r ewovLll techniques, i t vms the purpose of t his study 
to fomulate a topical dosage form that L'!a.Y be apphed to denuded 
c..reas of the skin ''i thout i nunction. Using the cor!ccpt of topical 
films, a dosar;e for m "ras for!!!ulated that is highl y water soluble , 
f l exible , and edhercnt to both denuded and illt<.:ct "-rees of the :::ldn. 
In order to develop a dosage form u i th these char acteristics , 
a vehicle consi sting of t-iiranol 2t·1CA Hodified, sorbitol, dextrcn , 
c:.nd wate r \'.'as formulated . 'I'his hydrO})hiJic, aerated film \WS 
compounded und evulua t ed by the use of :i.n vi_trQ. and. il]_~~L.9. 11ethods . 
In addi titm , ::;tability tests v:ere r:erformed to immre c.deq_uate 
shelf l ife . 
'l'hc rtJl ease of therapentic agents irL vi tr:g_ froo dry foam formu-
lations vlas cor~pared Ni th t.~.1at of co:r.r espor.ding ointl:le:lt bases , 
utilizing a modified aga1· diffusion test . Using Fseadol:lonas seruginosa 
as the tent bacteria , these t est s shO\ofed t hat silver ni tra. te and 
s ilver sulfadiazine produce sicrnifi cantly lorger zor.es 0f inhibition 
when used tiS t he cry foam r a ther than as an oint n:ent . Ho\o~ever , 
me.fenide a.cetate and gent e..micin sulfate produced equivalent r elec.s e 
rates f r om both t he dry foal:l and ointment . 
·I n vivo. studies demonstrated tha t incidence of infection '.lS:i.ng 
the burned , infected guinea pig was statistically equi valent when 
rnafenide acetate was applied as either the dry foam or the commercially 
available ointment . A therapeutic r er,i roe using silver sulfadiazin~ 
dry foam produced s ignificantly better results than vrith the 
corresponding ointment, i f therapy was initiated one-hal f hour after 
inoculating the animals . However, by delaying ther apy for 72 hours, 
incidence of infection after trea t ment v:i th ei thcr preparation v:e.s 
without s i gnificant difference. 
As t he dry f oa@ formulationo deoo1~trateu not less than equivalent 
efficacy when compar ed to ointment bu.ses in curr ent usage , it appears 
t hat u medicated dry foru.1 11ill be of va l ue as a vehicle for topical 
use . By clicinating t he need to spread the dosage forw. onto skin 
lesions I:l~~ually , the dry foaL1 may prove to be of value i n trea t ing 
the seriously burned patient. Further, by the use of a h i ghly water 
soluble t opical dosage for m, r err:ovl:il may be accompl ished v~i thout injury 
to denuded areas . 
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INTRODUCTION 
The massive burn produces a complexity of serious 
problems which must be handled in a comprehensive manner. 
The intensit;y of pa in is perhaps obvious to any who have 
had even minor thermal injuries. However, fluid and elec-
trolyte shifts and shock response may pose a:n immediate 
life threatening condition in the massively burned patient. 
In addition to these, invariably there is maj or disrupt ion 
in the anatomy and anatomical function of the skin. Dis-
ruption of normal skin structure opens avenues for loss of 
fluid and entry of microorganisms into the body • . Invasion 
of burn vlOunds by bacteJ:ia may present a potentially life 
threatening hazard to the patient, should their e stablish-· 
ment result in septicemia and abnormal wound healing. 
is primarily toward these problems that topical theraj:·Y Dust 
be considered as a major component of the therapeutic ::::"es i -
men employed in the total management of the patient. I t is 
the intention of this study to address itself to considera -
tions of methods and materials employed in topical anti·-
bacteria l therF.lpy for the severely burned patient. 
Histor:y of Topical Burn Tber2:.J2;Y. 
As interest in therapy for those injuries caused by 
heat dat es back to the early days of mankind, several 
authors have r eviewed the history of topical burn therapy (1,2) .. 
Hippocrates suggested the f'ollovJing treatment: 11Having 
melted old swine seam and mixed it with resin and bitumen, 
and having spread it on a piece of cloth and v1armed it at 
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the fire, apply the bandage .. 11 By the seventh century, A.D., 
local therapy consisted of the application of various 
emollient preparations.. Oleaginous, emollient substances 
were also recommended by Pare in the sixteenth century for 
topical treatment of the burned patient. During the nine-
teenth century, Ballingal, a British surgeon, recognized 
that mortality following a severe burn was due to a 
febrile condition. In spite of this diagnostic insight, 
purgation and bloodletting were considered to be the treat-
ment of choice. Still, oils and vJaxes continued to be the 
foundation of topical therapy. In 1858, the local use of 
tannic acid was suggested in an attempt to coagulate the 
vmund surf'ace._ln 1925,_Davidson (3) renev.Jed interest · in 
the use of escharotics by the introduction of a tannic &eid 
spray., It was believed at that time that tar..nic acid.! t:: :.. ther 
alone or in combination vJith silver nitrate, decreased fluid 
loss, relieved pain, and produced an effective eschar. It 
\-.ras not until 194L~ that the use of tannic acid was abandoned, 
when McClure determined that this agent was hepatotoxic (1,2)~ 
VJi th the advent of the sulfonamides, penicillins, and 
other antibacterial agents, clinical trials ~11ere initiated 
in an attempt to decrease the incidence of deaths due to 
burn \.Vound. sepsis. HovJever, by 1953, studies demonstrated 
that septicemia was still of primary concern and the most 
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common cause of death, even though supportive care \·Jas 
instituted to prevent the shock associated with most major 
burns. In the 1960's, frequently implicated microorganisms 
included species of Staphylgcoccus, Escherichia, Pseudomonas, 
Aerobacter, and Proteus. In addition, the major cause of 
death in the severely burned patient had shifted from 
Staphylococcal to Pseudomonas septicemia ( Li·-7). 
Prior to 1964·, 60% of the burn patient deaths vJer.e 
usually attributed to burn ,..,ound sepsis (8)" Since that 
time , invasive burn \IJOund infection has occurred at an 
annual rate of 5-16%. In burns of less than 30% body surface 
area (B.S .. A.), death is an infrequent occurrence . Ho,·.rever, 
death occurs in 69% of those patients experiencing 50% B.S~A .. , 
or more. Of these , death can be attributed. to Pseudomonas 
septicemia in 40% of the cases (4). As more tt.en one million 
people per year in the United States are burned badly ·enough 
to warrant hospitalization, Goldman, IJarson, and Abston (9 ) 
have described the burn injury as the 11 Silent Epidemic .. . , 
This is evidenced by the fact that seven persons per 1000 
population are injured by contact vrith hot objects.. Of 
these, four deaths per lOO,QOO population can be expected (2 )9 
General Cons iderations of the Burn Patient 
In order to differentiat e the various depths of thermal 
injuries , a commonly used classification divides burns into 
three categories: first degree , second degree , and third 
degree (2). First and second degree burns are frequently 
referred to as partial thickness burns , while the third. degr ee 
lj. 
burn is described as a full thickness injury . The first 
degree burn involves only the outer l ayers of the epidermis . 
This burn is characterized by erythema that appears aft er a 
short period of latency. Tissue damage is quite superficia.l, 
and because of this, minimal complications occur, except for 
slight pain, erythema , and possible edema. As this is a 
very superficial thermal injury, the continuity of the skin 
is not interrupted, infection rarely occurs, and healing is 
usually uneventful. \•Jithin several days, the burned areas 
slough off in small scales ''Jith no long term effects (1) . 
The second degree burn involves an entire segment of 
the epidermis. This partial thickness thermal injury can 
be distinguished from the first degree burn by the presence 
of vesicles at the involved site. Considerable subcutaneous 
edema is · evident along with erythema and. :pain. In the abs !?lee 
of infection , he_aling will occur ,.,ithin ~eks as the 
epithelium regenerates. In the event o:f infection , a. second 
degree burn may convert to a full thickness injury \vit~ -the 
characteristics and complications associated \vith this t;rpe 
of thermal injury (1,2). 
The third degree or full thickness burn may be a life 
threatening injury. Burns of· this type destroy the dermis, 
subcutaneous tissue, or skeletal muscle resulting in possible 
shock , septicemi a , and death. In addition , thrombosis , 
increased capillary permeability, and edema surrounding the 
burned area are indicative of a full thickness burn. l!urther, 
the burned area appears dry, l eathery, and. charred . Pa:in is 
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not an immediate factor, as the area is a lmost insensible 
due to the destruction of the terminal nerve endings . The 
resultant dead tissue of the full thickness burn is referred 
to as an eschar. As the eschar consists of dead tissue with 
no vascular supply, normal body defenses against infection 
are r el atively non-existent. For this reason, the prevention 
of local infection and septicemia as a complication of a 
third degree thermal injury is of prime consideration (1,2). 
Initial bacterial grovrth usually occux·s on the surface 
of the burn wound (4). This groV<Jth is frequently referred 
to as supra-eschar bacterial colonization. This surface 
grm·rth, if not arrested, is followed by intrafollicular 
colonization into areas of d.estroyed hair follicl es.. Once 
this occurs, bacteria readily penetrate through the eschar 
and then into subcutaneous tissues. Bacteria.l infiltration 
of these tissues is referrBd to as intra-eschar and 
eschar colonization, respectively (2). 
In addition to determining the burn depth and the l~vel 
of bacterial involvement, it is necessary to estimate the 
extent of the injury prior to instituting appropriate thera-
peutic measures. Traditionally, the "rule of nines" bas 
been employed to provide an estimate of the extent of surface 
area involvement. This method considers the major body parts 
as multiples of nine, allocating 9% to the head and neck , and 
9% to each upper extremity. The anterior trunk, posterior 
trunk, right and left lov1er extremity are each assigned lB% ~ 
with the perineum one percent.. As this s imple method of 
estimation i s not totally accurate, other methods use 
t ables describing surface area of body parts in relation 
to age , height, and. weight. Along vJi th the use of burned 
surface area as an aid in selecting appropriate fluid 
replacement therapy, the probability of survival can be 
est imated wit hin reasonable limits, since survival is pro-
portional to the extent of the thermal injury (1). 
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An older type of cl assification, described by Artz and 
Reiss (10), suggest categorizing burns as minor, moderate , 
and critical. f1inor burns include partial thickness thermal 
injuries of l ess than 15% B.S. A., or full thickness burns of 
less than 2% B.S~A. Partia l thiclcness burns of 15 to 30% 
B.S .. A. and f ull thickness burns of less than 1096 are con-
sidered moderate burns, providing the hands, face, or 
genitalia are not involved.. Critical burns a.re those con:-
plicated by respiratory tract injury, full thickness burns 
of the f ace , hands, or genitalia, full thickness burns 0:: 
more than 109.6 B.S.A., and partial thickness thermal injm·ies 
of more than 3096 B.S. A. In addition el ectrical burns, deep 
acid burns, and those involving major soft tissue injury ruay 
be categorized as critical burns. 
As mentioned previously, alterations in fluid and 
electrolytes in the massively burned patient poses a life 
threatening situation manifested as burn shock~ Severe 
thermal trauma results in a loss of circulatory integrity 
that culminates in visceral failure and often death, unless 
large volumes of biologically active fluids are adininist ered ( 11) .. 
As part of the inflammatory response , local t i ssue damage 
is a ccompanied by increas ed capillary per meabi l i t y and 
vas odilatation leading to a r apid loss of f luid from the 
circulation. This escape of fluid produces local edema , 
hypovolemia, and decreased r ena l function. Dist urbances 
such as these will lead to alterations in electrolyte and 
protein concentration. Although burn shock presents an 
immediate hazard to the burn patient, effective therapeut i c 
mana gement measures are available. In a ll but the most 
massive injuries, administration o.f adequate volumes of 
plasma-, blood, electrolyte solutions, dextran solutions, 
or a combination thereof, will enable the pat i ent t o over-
come the stress o.f the situation (4,12 ,13 )~ 
Current Practices in Loca l Th er apY 
In an att empt to mini mize and eradicate Pseudomonas 
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wound sepsis, topical therapy at the present time evolves 
around the use of gentamicin sulfate,a mafenide acetate , ~ 
silver nitrate , and silver ·sul fadiazine. All of these c:~ent s 
have demonstrated effectiveness in controlling invasive ~urn 
vJound sepsis. None completely eliminate bacteria from t he 
lesion, but will prevent extensive suppuration, especially 
that due to Gram negative bact eria. 
When 0. 5% aqueous silver nitrate is employed topically , 
dressings must be continuous l y s aturat ed in or der to keep 
a - Hereinaft er referred to as gentamicin . 
b - Hereinafter r eferr ed t o as mafenide . 
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this antibacterial in contact with the burn \.-J ound . Usua lly , 
dressings are moistened at two hour intervals, and ar e changed 
every bwlve hours. It should be not ed that t he hypotonicity 
of silver nitrate can cause a severe degree of electrolyte 
loss and, therefore , supportive therapy to avoid hypona-
tremia, hypochloremia, and hypokalemia must be considered . 
The development of methemoglobinemia is a rare occurrence 
that leads to discontinuance of silver nitrate therapy. The 
use of silver nitrate in established infections of de~p t hird 
degree burns is of questionable value since t he diffusibility 
of this therapeutic agent is extremely lov1. A further dis-
advantage associated with the use of silver nitrate involves 
its instability upon exposure to light. The deterioration 
that occurs is manifested by the widespread s t aining of it ems 
that come in contact with it (14-16). 
The use of mafenide cream also greatly reduces Pseudomonas 
sepsis. However , use of mafenide can result in severe meta-
bolic acidosis secondary to its r apid diffusion throug~ -:b.e 
burn wound. into the blood stream. In high concentrations , 
rnafenide inhibits carbonic anhydrase which may lead to alt er a-
tions in pH. Therefore , while mafenide's deep percutaneous 
absorption is of value in treating deep infections, i t may 
pose systemic problems in the form of metabolic acidosis . One 
factor that has l ed t o a lack of patient acceptance is t he 
moder ate pain that is experienced upon application of maf eni de 
cream to burns. Alt.bough described as a moder at e pa in, cer tain 
patients .r equire systemic analgesics to minimize this side 
effect, and occasionally refuse the medication (14-17). 
Silver sulfadiazine cream, an investigational drug 
product, is currently being subjected to clinical study. 
Clinical evaluation has identified fe\'! problems associated 
\vith the use of this agent other than minimal percutaneous 
absorption (14). 
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Gentamicin cream has rarely been implicated as a source 
of drug related complications when used in burn therapy. 
However, penetration to the dep·ths of the burn wound does 
not occur to the extent noted for mafenide (14-16). 
Although the above mentioned therapeutic agents have 
been used successfully to treat Pseudomonas wound sepsis , 
concern has been expressed recently vJith respect to the over-
grov~h of non-susceptible organisms. Further, pathogenic 
fungi have been noted to colonize burn v10unds. Because of 
this, it has been suggested that the fungi have emerged as 
a new infectious threat to the burn patient (14). 'l1o cm::bat 
this, the use of povidone iodine ointment is presently -:.ncier-
going investigation to determine i ts efficacy in eradicat ~ng 
fungal infections of burn wounds (18). 
In conjunction v:Tith the routine use of the above medicated 
applications, supportive local care must be initiated in oro.er 
to reduce the mortality associated with thermal i njuries.. The 
primary goals of this care are the prevention of infection and 
the closure of the lesion as soon as is possible. For this 
reason, removal of dirt and detached epithelium must be accom-
plished. Initial cleansing of the burn with bland soap and 
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vmter will aid in t he removal of extraneous material . Also , 
initial excision of all dead t i ssue may be indicated since 
devitalized tissue provides an excellent culture medium for 
bacterial proliferation (2). 
As part of supportive l ocal care, the use of occlus ive 
dressings, such as sterile gauze, petrolatum gauze, or medi -
cated gauze dressings may provide a beneficial effect. The 
occlusive dres sings are absorptive and, therefore, aid in 
keeping the wound surface dry. Further, decreased conta !":!ina-
tion of the wound can be expected clue to the presence of a . 
protective covering. Hovrever, the use of gauze impregnated 
with ointments can present certain problems. According to 
Hagerty (19)~ drainage from the lesion may be inadequate and 
occasionally result s in excess maceration and reduced epithe-
lia lizati on. The r eduction i n epithelial reeeneration and 
the increase in maceration could produce a higher incidence 
of infection. 
In contrast to the use of occlusi ve dressings, t he 
exposure method has been described as a useful part of local 
wound care. By keeping the wound exposed, the exudat e on the 
surface of the burn will dr y and form a crust. This cr~st 
s erves as a natural protecti ve covering for the wound and 
epithelial regeneration may proceed beneath the crus t unless 
infection occurs. However, this method requires that s pecial 
provisions be made to keep the patient warm (20 ). 
Removal of the eschar must also be accomplished as part 
of the supportive local care of t he patient (2 ). Although 
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some risk is involved, eschar removal i s a vital part of the 
r epair and regrm·rth of the area . Allowi:c.g the eschar to 
remain in place can provide a culture media v1hich will per"· 
mit rapid multiplication of bacter ia. Further , an eschar 
locali?.ed on the upper chest may inhi bit respiration if ne-t 
removed due to the constrictive action of the l esion (21~ 22) . 
Techniques that a i d in the removal of the eschar include fre-
quent changes of moist dressings, daily bathing in a Hubbard 
tank, and surgical debridement. A specific disadvantage o.f 
the surgical procedure is the added injury and insult to the 
already traumatized patient. Complications include undue 
hemorrhage ancl infect i on of the deeper layers of the ti ssue . 
Soaking the patient in water at 100°lt1 utilizing a Hubbard 
tank, although an effective method, involves the hazard of 
spreading infecti on by the bath 'ltrater or associated equip-
ment (2). 
Topical Vehicles in Burn Therapy 
Y.lith respect to the ointment bases in current use~ tbe 
traditional oil-in-water emulsion base has been selected by 
most manufacturers as the topical vehicle of choice in burn 
therapy. ~1a.fenidea for topl.cal application is commerci a1ly 
available as an ointment prepared in a water miscible emul-
sion base consisting of cetyl and stearyl alcohols , spermaceti , 
polyoxyl LJ.o stearate, polyoxyl 8 stearate, glycerin 1 ,.mter and 
a - Sulfamylon Cream, Winthrop Laborat ories , D.ivision of 
Sterling Drug, Inc .. , New York, N. Y. 
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suitable preservatives (23). The vehicle for gentamicin 
creama is described as a bland emulsion composed of stearic 
acid , propylene glycol monostearate, isopropyl myristate , 
propylene glycol , pol yoxyethylene sorbitan monopalmitate , 
sorbitol, and water (21.J.). Nitrofurazone,b which has been 
widely used in the treatment of infected lesions is present ly 
marketed in two dosage forms. The ointment formulation co:1.-
sists of gl ycerin, cetyl a l cohol, liquid petrolatum, an 
ethoxylated fatty alcohol , preservat i ves, a.11d water (25) . A 
vmter soluble basec of mixed polyethylene glycol polymers is 
also available for topical application of nitrofurazone. 
Although presently avai l abl e for investigational use only , 
si lver sulfadiazine is also applied in an oil-in- water ernul-
sion base (26 ) . 
In comparing the effectivenecm of an aerosol and tlrr'ee 
creams containing 8.5% mafenide, Dressler et al (27) , moni-
tored both mortality rates and bacterial counts in burne·i 
rats. After burning each rat for ten seconds at a tempe:-·ature 
of 98°, d each animal was infected vli th one ml. of an l B r.ou1~ 
broth containing Ps. aeruginosa. Three hydrophilic cream 
vehicles containing stearyl .and cetyl alcohols, glycerin~ 
a - Garamycin Cream, Schering Corporation, Bloomfield, N. ,J . 
b - Furacin Topical Cream, Eaton Laboratories, Division of 
The Norvli.ch Pharmacal Co., Norwich, N. Y,. 
c - Furacin Soluble Dressing, Eaton Laboratories , Division 
of The Nor\vich Pharmacal Co., Norvlich, N .. Y. 
d - Hereinafter, temperatures are listed in degrees Centigrade. 
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spermaceti , methyl paraben, and propyl paraben were evaluated. 
Sodium lauryl sulfat e or one of t vJO other surface active 
agents , not designat ed , were included :in the cream bas e f ormu-
l ations. The a erosol was formulated in an undefinecl hydro-
philic bas e . The mor tality r ates in ani mals treateo. v!ith the 
mafenide creams ranged from 5 to 10%. Util izing the corre-
sponding medicated aerosol, a mortality rate of 20% v1as 
observed. Average mortality r ates for the nontreat ed con-
trols \'Jere 639&. In addition, qualitative bacteriologica l 
studies of the seeded animals provided similar r esults . 
Lindbei·g, Moncrief , and Hasan (28) utili zed twice daily 
applications of mafenide in a water soluble base consisting 
of stearyl and cetyl alcohols , glycerin, and 62% y,rater . A 
rat model vJith a scald of 20% B.S.A. was us ed to evaluat e t he 
effectiveness of the product. Untreated animals suffered over 
90% mortality vJhile the treated groups survi ved the Pseudomonas 
challenge . However, in animals treated only once a day Kith 
the medicat ed cream, mortality rat es from 20% t o 40% ~e~e 
observed . 
A comparat ive evaluation of silver sulfadia zine and 
mafenide in the burned rat model was performed by Dress l er 
and Skornik (29). After burning the backs of r ats for t en 
0 . 
seconds in 98 water, the animals v1ere seeded \·lith one ml . 
of an 18 hour culture of Ps. aeruginosa . Topi cal th(:~rapy vms 
initiated two hours after seeding . Monitoring mortality 
during a 21 day study, it was found that over 909.6 of t he 
ani ma l s in the control groups died . The mortality rate for 
1'+ 
animals treated with 8. 5% mafenide cr eam wa s ll.J·. 59S, vJhile 
20% of those treated with 30 mMoles of silver sulfadiazine per 
kg. of Neobase Ointmenta died. The medication was applied 
once daily ru1d no attempt to remove the eschar or residual 
ointment was made prior to treatment. Subeschar , blood ~ and 
liver bacterial counts were made . 
Fox, Sampath, and Stanford (30 ) compared the effica cy 
of silver sulfadiazine and mafenide in ointments . Burns 
were produced by immersion of the dorsum of rats for ten 
seconds in water at 95°. The animals were inoculated one 
hour post burn vJi th one ml. of an 18 hour broth culture of 
Ps. aerugi_nosa. Silver sulfadiazine, 1%, was applied bot h 
in Neobase Ointment, and in a similar cream prepar ed specifi-
cally for the study. Mafenide was used as the commer cially 
available Sulfamylon Cream. Application of the test prepa.:·a.·-
tion and corresponding control materials were made once daily. 
Using percent mortality as the criteria f or evaluation, 92% 
of the untreated controls and 100% of the Neobase t:rea:::ea.. 
animals died. The mortality rate for animals treated vJi t h 
mafenide was 12.5%, v1hile animals treated with the silver 
sulfadiazine preparation suf,fered 11.2% mortality . Postmortum 
studied o.n tissues shovmd high bacterial counts in the untreated 
controls but no positive blood cultures in the animals treat ed 
with mafenide or silver sulfadiazine. 
Using mice anesthetized v..rith ether and scalded in \·mter 
a- Available from Burroughs Uellcome and Co., Hesearch 
Triangl e Park, N. c. 
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at 68° for six seconds, Fox (31) determined the effectiveness 
of various topical therapeutic agents effective against 
Pseudomonas . Local application of 0 . 5% silver nitrate solu-
tion or 8.5% mafenide cream reduced mortality from over 80% 
to approximately 509G.. The topical application of' an ointment 
containing 30 mlV1ol e/kg . of silver sulfadiazine reduced mor-
tality to approximately 20%. 
Rosenthal (32) immersed mice to the upper third of the 
thigh for five seconds in water at 70° to produce full t:C.ick-· 
ness thermal injuries. After infecting tbe burr..ed animals 
with Pseudomonas cultures, several locally effective agents 
v1ere eval uated. Survival rates in those treated with mafenide 
cream was 92% and in those treated \1/ith 0.14% chlora.mphenicol 
in a similar base, 809G .. Application of 0, 5;.6 gentamicin, 0 ./1-7~ 
neomycin, c:md 1% streptomycin gaye complete protection.. A-nti-
biotics that were without therapeutic effect included p ol;ymyxin, 
penicillin G, silver nitrate , and tetracycline .. 
In a similar study by :!!'ox , Rappole, and Stanford C'53) , 
the tail, pelvis, and both hind legs of mice were immersed 
for five seconds in water at 70° .. After burning , the tail 
vms immersed in a 1:1 dilution of an overnight culture of 
Pseudomonas . Topical therapy \vas initiated four to six hours 
after infection and once daily thereafter. Tbe percent mor-
tality for the untreated control s vJas 80%. Treatment ;,vith 
0.1% gentamicin cream or 8 .. 596 mafenide cream resulted in over 
80% mortality. The use of 1% silver sulfadiazine result ed i n 
25% mortal ity. It has not been determined i f this in vivo 
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animal model util izine; tail inoculation was a factor in the 
dramatic results obtained. 
The use of mortality rates as the primary c r i t eria of 
effectiveness may pose prob l ems.. For example , in studying 
bacterial infection in burned animals , it is necessary to 
distinguish between deaths due to the trauma of the burn and 
those resulting f r om inf ect i on with the test bact eria. In 
order to minimize death due t o the shock and trauma associated 
vli th inflicting a l arge , f ull thicJ.r.ness, thermal injury, 
McRipley and Garrison ( 34) suggest administrat ion of f luids 
to aid i n ove r coming the shock and trauma. They a ccomplished. 
burning by means of a steam chamber which consists of a metal 
cylinder v.Ji th one side molded in the general shape of the back 
of the animalo The anesthetized anima l s v1ere placed. i n the 
chamber and burned for 30 seconds. 
In addition to the effect of shock and t rauma aftei' burn-
i ng , the virulence of the test organism in the animal n~oC.el 
may a lso affect the mortality r ates observed. Fo}~ (30) .found 
that most strains of Ps. aeruginosa isolated from hospitalized 
pat ients were l ethal to burned mic e but that rats were r ela-
tively res i s tant and died after seeding with certain strains 
only. Lindberg, Moncrief, and ~1ason (28) reported varying 
mortality r ates due to Pseudomonas virulence in burned. rats~ 
In animals s eeded v-lith intensely virulent strains (VA-13LJ-) 
follo\IJed by once daily application of mafenide cream , mor-
tality r ates ranged f rom 20% t o 4-096. Ho-v.rever , all rats 
seeded with a l ess virulent strain (12-4-4-59 ) and. treat ed 
in a similar manner survived. Because of the variable 
effect of virulence, shock , and trauma after burning , i t 
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may be of value to devise studies utilizing parameters based 
upon the presence of the test microorganisms rather than the 
fatal effect of their presence. 
other Potentially Useful Dosar;e Forms 
In spite of the refinements that have been made in oint-
ments as a dosage form for the treatment of massive burns, 
inherent disao.vantages are evident, especially vJhen app1ica-
tion to denuded areas is indicated. As semisolid dosage for:n s 
must be physically spread onto the involved site as a film, 
it is possible that this application technique may result in 
a painful experience for the massively burned patient . Further, 
the solubility characteristics of ointments may present prob·-
lems Hhen. efforts are made to remove the ointment .from the 
denuded area . 
In order to improve loca l therapy, several novel cpyroaches 
to topical dosage form technology have been used. P~ce7so~ (35) 
formulated a water soluble protective f ilm for use on de~uded 
areas such as a full thickness thermal injury. This formula-
tion consisted of cellulose.derivatives, glycerin, surfactants, 
and v~ater. Upon casting and drying the film-forming solution, 
the preparation appears as a highly porous film-like banda~e. 
In addition to its use as a protective· dressing, Anderson 
suggests that medicated appl ications lvould be of value in 
treating open skin l esions . 
V.b t a · 1 esa-e 1s 
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also a protective film for local use (36). 
However, this film is generated by means of a pressurized 
aerosol. This water insoluble mechanical protective con-
sists of an ethyl acetate-acetone solution of hydroxyvinyl 
chloride acetate, modified rosin esters, and sebacic acid. 
Although suggested for use on burns, skin ulcers, or other 
injured areas, the solvent system of this aerosol produces 
transient pain upon application to sensitive surfaces. 
Sciarra and Gidvmni (37) formulated 1rarious \<Jater insolu-
ble, film-forming aerosols containing gentian violet. Of 
prime importance was the ability of a polymeric film to be 
sprayed onto the skin and protect the skin against excessive 
moisture loss . Further, the ability of t he f ilm to facilitate 
prolonged contact betv1een an active ingredient and the skin 
was considered. Acrylic and polyamide resins were used in 
combination v1ith plasticizers, namely, tributyl citrate,_ 
hexadecyl alcohol, and lanolin derivatives. The in v·-it-r-o 
release of gentian violet from the films was determined . 
Using similar film- forming aerosol formulations, Sciarra 
and Gidwani (38) determined rates of drug release and magr..i-
tude of binding to the film polymers. Cetyl PJTidinium 
chloride and benzalkonium chloride were selected as thera-
peutic agents to demonstrate the possibility of utilizing 
an aerosol spray as a 11 spray-on bandage. 11 A mixed polymer 
solution of a polyamide resin and ethyl c ellulose with 
a- Available from Parke, Davis and Co., Detroit, Mich. 
tributyl citrate as the plasticizer appeared to be best 
suited for drug release. 
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Although not in use as a dosage form, Absorbable Gelatin 
Spongea may be considered to be a type of dry foam (36,39 ). 
This pliable aerated substance is cast from a treated gelat in 
solution to render it insoluble in \vater. As i t absorbs and 
holds \'lithin its meshes many times its v.reight of whole blood , 
Absorbable Gelatin Sponge may aid in providing hemostasis 
during surgery. 
Because of the disadvantages of ointments already 
described, it may be assumed that they are not an ideal 
topical dosage form for use on the severely burned .patient . 
Therefore, using the conc ept of topical f ilms , it is the 
purpose of this study to formulate a topical medicament that 
may be applied to denuded areas of the skin vlithout inunct~_on .. 
A further requirement is that the proposed dosage form be 
highly \!later soluble, flexible, and adherent to both der;.!ld.ed 
and intact areas of the skin. Finally , it must be de~c~­
strated that it provides equivalent efficacy when coru:parsd. 
to the ointment bases in current usage . 
In order to develop a dosage form with those characteris-
tics, it was decided to formulate a topical vehicle i n the 
for m of a hydrophilic foam. HO\·Jever, r ather than utilizing 
an aerosol as the method of genera,ting the foam, a foam in 
the form of an aerated, dry film vlill be compounded. Once a 
a - Gelfoam , The Upjohn Co., Ka l amazoo, I1'lich. 
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suitable dry foam has been formulated , both i n vitro and 
in vivo evaluations will be made to compare the effective--
ness of medicated dry foams with comrn8rcially available oint·-
ment preparat i ons. 
EXPERII1ENTAL 
Dry Foam Formulation 
In developing a hydrophilic dry foam formulation for 
topical use , combinations of ingredients \•Jere selected on 
the basis of their water solubility, foaming characteristics , 
and accepted usage in human subjects. Based upon these 
parameters,- many dry foam formulations were prepared, ev-alu-
ated , and in most cases, rejected as a useful dosage form. 
This information is summarized in Table I. 
I n an attempt to provide optimal foaming properties, 
surfactants, namely dioctyl sodium sulfosuccinat e,a poly-
oxyethylene so:rbitan mor1olaurate,b and f-1iranol 2111CA Modified ,c 
were included in the formulations. Dioctyl sodium sulfosuc-
cinate is a surface active agent that has been used as an 
orally administered laxative and has been useful in a vc~iety 
of pharmaceutical formulations as a 1.-Jetting agent (36, ~-0) . 
Polyoxyethylene sorbitan monolaurate, a nonionic emulsifier , 
is used in the formulations of emulsions for both oral and 
parenteral administration (36). Miranol 2MCA Modified is an 
amphoteric surfactant with detergent, emulsifying and wetting 
a- Aerosol OT, American Cyanamid Co4, Wayne , N. J. 
b - Tween 20, Atlas Chemica l Industries , Vlilmington, Del. 
c - Available from Tbe 1'-liranol Chemical Co., Inc., Irvington, 
N. J. 
TABLE I 
Composition and Eval uation of the Experimental Dry Foam Formulations 
Gross 
Formulation 
Dextranb 
Sor bitol 
T- 20d 
Physical 
Nui-nbera \r/ater So ln. Glycerin D?Sc Niranole Evaluation 
C- 1 45 30 19 . 5 11 . 3 1 slowly 
soluble; 
sticky 
C- 2 28 15 6 . 5 3.9 0 . 25 sticky 
C- 3 28 15 6 . 5 2 too porous 
C- 4 28 15 6 . 5 3 same as 
C- 3 
C- 5 28 10 6.5 l more 
flexible 
and less 
sticky 
than C- 1 
C- 6 38 . 5 7 5. 2 I 0.5 similar to 
C- 3; 
slightly 
sticky 
C- 7 43 . 5 5 2. G 0.25 too 
fragile 
C- 8 LJ-2 5 ?.9 
I 
0 . 2 too f\J 
fragile i\) 
TABLE I (continued) 
Gross 
Formulation b Sorbitol D)Sc T- 20d Miranole Physical Numb era Water Dextran So l n . Glyceri::J. Evaluation 
C- 9 20 4 1 . 3 I 0 . 1 insufficient 
plasticity 
C- 10 20 4 2.6 I 0.1 good 
plasticity; 
non- sticky; 
liquefies 
quickly 
G- 11 19 4 2.6 0 . 1 same as C- 10 
C- 12 19 4 2 . 6 0.05 same as C- 10 
C- 13 19 4 2 .. 6 0 . 02 insuf ficient 
aeration 
C- 14 19 4 2 . 6 0 . 05 same as C- 10 
a - Quantities are listed in g . 
b - Dextran T 70 was used as t he dextran componsut for all formulations except for C- 14. 
Sigma Dextran was used i n C- 14. 
c - Diocty1 Sodium Sulfosuccinate . 
d. - Tween 20. 
c - I'-Iir~'1o1 2 l"'~CA fviodified. 
PJ 
·~ 
properties (41). As t hi s agent is non-irritating to skin 
and mucous membranes , it is frequently included. in "no sting 11 
shampoos ( 42) o The lO\tJ order of t oxicity and high foaming 
pov:er of these were essential considerations in their selec-
tion for the experimenta l product. 
In order t o pr ovide a hydrophilic base or matrix for the 
dry foam, Dextran T 70,a and Sigma Dextran,b with an average 
molecular v1eight of 86,900, \'Jere included in the experimental 
f ormulations. The dextrans ar e freel y water soluble polJ~ers 
of glucose. Therapeutic indications for Dextran 70 include 
the intravenous infusion of a 6% s olution as a plasma expander 
in the prevention or treatment of hypovolemic shock (36, 4-0 ). 
For added plasticity upon drying , 70% Sor~it ol Solution ,c 
U S P d Gl . d u s p . 1 d d . . i ' ••• , an ycer1n, ••• , were 1nc u e 1n var1ous :ormu-
lations . Along with its use as a humectant and sv1eetener , 
Sorbitol, u.s .. P., has been used as an osmotic diuretic admin-
istered intravenously as a 50% solution. Glycerin is a 
pharmaceutical solvent useful as a humectant and emoll;i.en7; 
in topical preparations ( 36). 
In addition to variations in composition, variations in 
formulation techniques were made, such as drying conditi ons , 
blending time , dissolution temperature, moisture content , and 
a -Available from Pharmacia Fine Chemicals, Piscataway, N .. J. 
b - Available from Sigma Chemical Co., St. Louis, Mo . 
c- Sorbo Solution, Ruger Chemica l Co., Inc .. , Irvington, N. J. 
d - Available f rom Ruger Chemica l Co., Inc., Irvington, N. J-.. 
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thickness of the cast foam.. Based upon subj ective evaluation ~ 
the most promising dry foam formulation , C-- lL~, Has sel ect ed 
for furt her study in order to compare its effectiveness vJith 
ointments as a dosage form for topical application of common 
agent s used in local burn therapy. Formul ation C-14 consists 
of the f ollowing: 
Sigma Dextran • • • • • ~ • • 
Sorbitol Solution, U. S. P • • • 
l1iranol 2l\1CA f\1odified • • • • 
'vlater • • • • • • 0 ... . .. . . 
4 .. 0 g . 
2.6 g . 
0.05 g. 
19 .. 0 g . 
The dextran v.Jas dissolved in 19 g . of vmter at a temperature 
of ?0° to 75° on a water bath.. The remaining ingredients were 
addeo. and the entire solution \\•as whipped i:'or ten minutes with 
an electric beater . The resultant foam was cast on a teflon 
coated pan to a depth of tv:o mm., and dried at a temperature 
of 40° to L;..5° for 20 t o 30 minutes in a laborat ory oven. 
After drying , the moisture content of the dry foam '"'as deter--
mir!ed using a Genco Moisture Balance .. a Average values .for 
these measurements were 10%. In addition t he lique.fact.:.~n 
time of the dry foam was determined.. It was deter mineC. tb.at 
2 2.5 em. of the dry foam liquified in 0.1 ml. of wate:r· at 
ambient temperature in 20 seconds. 
Batches of t he dry foam formulation v1ere prepared con--
taining each of the f ollowing t her apeuti c agents in t he 
concentration listed: b 8 .. 5% mafenide, as the acet ate; 0 . 2% 
a- Centra l Scientific Co., Chicago, Ill. 
b -- Sul.famylon Powder, Sterl.ing-ltlinthrop Research I nstitute , 
Rensselaer , N. Y. 
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nitrofurazone;a 0.196 gentamicin sulfate;b 0.5% silver 
nitrate; c and , 1, 2, and 3% silver sulfadiazine. According 
to the method of Fox (31,43), silver sulfadiazine wa s pre-
pared by mixing 27 g. of sodium sulfadiazinec with 17 g. of 
silver nitrat ec in 100 mls . of water. The precipi tate v;as 
washed, coll ected, and dried to constant Vle i ght at a tempera-
ture of 50° to 60°. 
Visual observation of the medicated formulations b efore 
drying shov1ed that the nitrof urazone and the silver sulfa-
diazi ne preparations appeared as light, fluffy, i'irm , foams 
similar to that of· the nonmedicated C-14 formulation. How-
ever, the mafenide, gentamicin , and silver nitrate formulat j ons 
did not have this consistency. Rather , after blending~ the 
mixture appeared slightly fluid . In spite of this altered 
appearance , all medicated i'ormulations were cast and d r i e d. 
as ahove, and s_u_hjected to in vitro testing. 
In Vitro Evaluation 
As Ps. aeruginosa has been frequently implicated a2 ~he 
causative bacter ia· in burn vJOund sepsi s, a modified micro-
biological agar diffusion test was utili zed to compare the 
effectiveness of the dry foam vlith ointments as a vehicle 
for therapeutic agents effective against this bacteria (44). 
a - Furacin c·rystal s , Eaton Laboratories, Division of I11ort on-
Norwich Products, Inc., Norwich , N. Y. 
b - Garamycin Injectable, Schering Corporation, Bloomfield, 
N. J • 
c- Availabl e from Ruger Chemical Co. , Irvington, N. J . 
The in vitro ef fectiveness of the medicated dry foam 
preparations was compared with the corresponding commer-
cially availabl e ointment formulations, namely, mafenide 
a ·t f b d t · · c cream, n1. ro urazone cream , an gen amJ..c J..n cream. 
Although not commercially available, 0 .5% s ilver nitrate 
in Neobase Ointment,d and 1, 2, and 3% silver sulfadiazine 
in Neobase Ointment 1t1ere prepared extemporaneously and 
utilized in this study. 
After autoclaving sufficient quantities of Bacto 
Antibiotic Medium 2e at 121° and 15 psi for 25 minutes in 
an autoclave, approximately 20 mls. ,llere poured into 
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100xl5 mm. sterile disposable petri dishes . Upon congealing, 
0.1 ml. of Bacto Antibiotic I·1edium 3f containing an overnight 
inoculum of Ps. aeruginosa (A.T.C.,C .. No. 972l)g ,.ms spread 
onto the agar media with the aid Oj': a steril ~:: , L-sbaped glass 
rod. Using a syringe, each of fifteen penicylinders wa~ 
filled with approximately 0. 3 g . of the ointment forrrnll2.:;i on 
a - Sulfamylon Cream, 'vlinthrop Laboratories, Division cf 
Sterling Drug, Inc., NevJ York, N. Y. 
b - :B'uracin Topical Cream, Eaton Laboratories, Division of 
The NorvJich Pharmacal Co .. , Norwich, N .. Y. 
c - Garamycin Cream, Schering Corporation, Bloomfield, N. J. 
d - Available from Burroughs \'lellcome and. Co., Research 
Triangle Park , N. c. 
e -Available from Difco Laboratories, Detroit, Mich. 
f -Available from Difco Laboratories, Detroit, Nich. 
g - American Type Culture Collection, Rockvil l e , Md. 
28 
under investigation. Penicylinders \·Jere pl aced upon the 
seeded agar, and incubated overnight at 37° . Penicylinders 
filled v1ith Neobase Ointment s erved as the control . Zones 
of inhibition vJere measured after 24 hours with a li'i sher-LiJ.ly 
Antibiotic Zone Reader~a 
The medicated dry foam formulations were . evaluat eO. in a 
similar manner. However, rather than utilizing penicylinders ., 
f ifteen discs of each medicated dry foam were prepared, eac~ 
with a diamet er of 7 mm. -- approximately equal to the dia-
meter of t he penicylinders . Nonmedicated dry foam discs \·!ere 
also prepared and evaluated as the dry foam control . 
As no zones of inhi bition were not ed for the control s, 
this information is summarized in Table VI I I , while the 
results of the in vitro determinations for the medicated 
dosage forws are listed in Tables II-VIII .. 
Preliminary Stability Studies 
Prel iminary tests were initiated in order to deterDi nc 
the stabi l ity of the dry foam. As a result of the in vi.tTo 
evaluations , it appeared that two types of o.ata were obtaiDed .. 
One type, the mafenide and gentamicin Cl.eterminations , de!!lon-· 
strated equivalent release from both the ointment and dr y 
foam formulations. The other type, the silver containing 
preparations , demonstrated greater release f'rom the dry foam 
. b t l d . . t t }~ th . 8 5ql t; an - 1e correspon J.ng oln men s. ! or ls reason , • p 
mafenide and 2% silver sulfadiazine v.Jere selected .for further 
a- Fisher Scientific Co. , Pittsburgh, Pa . 
TABLE II 
I n Vitr o I nhibi t ion of Ps . · aerQginosa By Dry 
Foam and Ointment Containing 0.5% Silver Nitrate 
Diameter~ Zone of 1nhibition(mm) 
0.5% Sil ver Nit rate 
Plate Ng_.__ ~ ~~ __ Dry Foam 
1 15.6 
2 10.2 
3 13.0 
Lf. 12.2 
5 12 . 6 
6 13 . 2 
7 14 . 0 
8 14 . 0 
9 10 . 8 
10 1L~ . o 
11 13 .2 
12 1L~ .. 8 
1 3 1p . s 
14 lO.L~ 
15 13. 0 
Mean 1b.s 
Standard Deviation ~ ,. 6 
p < 0 . 001 
0.5% Silver Nitrate 
Oi ntment 
9 .. 6 
12 . 2 
9 .. 4 
9.4 
8 . 0 
7. 5 
8 . 4 
10. 0 
8 . 6 
8 . 8 
9. 1 
8 . 0 
9. 8 
10 . 6 
9. 6 
9 .. 3 
1.2 
1'\) 
\..0 
Plate No . 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
l\1ean Diameter 
TABLE III 
In Vitro Inhibition of Fs. aeruginosa By Dry 
Foam and Ointment Contair.ing 1% Silver Sulfadiazine 
D.iamet er, ~Zone~ o.f- I!i .. h.Tbi-Fi on-(!Pin) 
1% Silver Sulfadiazine 1% Sil ver Sulfadiazine 
Dry Foam Ointment 
16.6 7 . 0 
14.0 7 . 8 
18.4 8 . 0 
15.0 8 . 6 
16.0 7 . 8 
16.0 8 . 8 
17.8 9. 4 
19.0 9. 4 
18.0 8 . 6 
18 .. 6 8 () .v 
15.0 11. 6 
19.0 9 . 0 
17.0 8 . 2 
18. 0 7 .5 
19 .l~ 7. 9 
17.2 8 .. 5 
Standard Deviation 1.7 . 1.1 
p < 0 . 001 
'->! 
0 
Plate No. 
1 
2 
3 
4-
5 
6 
7 
8 
9 
10 
11 
12 
13 . 
14-
15 
I11ean Diameter 
TABLE IV 
In Vitro Inhibition of Pse aeruginosa By Dry 
Foam and Ointment Containing 2% Silver Sulfadiazine 
Diameter;-uzone -of~ Inhibition(mm) 
2% Silver Sulfadiazine 
Dry Foam 
16.0 
20.7 
14-.0 
18.0 
17.6 
15.0 
17.8 
16.3 
15.2 
16 .. 4-
20 .. 4 
16.4 
17 .. 2 
15 .. 1 
13 .. 2 
l6L6 
2% Silver Sulfadiazine 
Ointment 
9 .4-
8 . 4-
8.4-
10.4-
9.2 
10 .. 0 
10.6 
11.0 
8.8 
10.4-
9 . 4-
9 .6 
9 . 0 
11 c; 
--•/ 
9 .0 
9 .7 
Standard Deviation 2 ' , · ~ 0 0 .. ./ 
p < 0.001 
\..'I 
1-' 
Plate No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Mean Diameter 
TABLE V 
In Vitro Inhibition of Ps. aeruginosa By Dry 
Foam and Ointment Containing 3% Si lver Sulfadiazine 
---- - ---~- - ~- - --~-{.---:;::::-'\ Di ameter, Zone of Inhibition\rnm; 
3% Silver Sulfadiazine 3% Silver Sulfadiazine 
Dry Foam Ointment 
20.0 10 . 0 
20. 0 10 .. 6 
23 . 0 11.0 
21.4 8 .2 
20. 4 8 . 6 
22.8 8 . 6 
17.2 9.6 
20.6 10.8 
22 . 0 9.2 
21.6 11.2 
18.0 9 . 0 
22.8 10. 0 
19.5 10. 8 
19.0 8 . 0 
20.2 10. 2 
20 .. 6 9 .7 
StandarQ Deviation l 7 
-· 
1.1 
p < 0 . 001 I 
\.,'-J 
f\) 
Plate No . 
1 
2 
3 
Lj. 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
i1can Diameter 
Standard Deviation 
P (Cal ) 0~05 
TABLE VI 
In Vitro Inhibition of Ps. aeruginosa by Dry 
Foam and Oi ntment Containing 8.5% Mafenide 
--Tiiameter, Zone of~rih.Ibl.tion(ffim) 
8.5% Mafenide 8 . 5% Mafenide 
Dry Foam Ointme_nt 
26.0 24.0 
28. 5 26.2 
28.0 24.2 
28.5 26.2 
29.0 
27.0 26. 4 
27 . 5 26.2 
27 . 5 26.8 
26.5 26.0 
25. 0 27 . 0 
20 .. 0 24.4 
30.0 25. 6 
2 9 . 0 26. 4 
2? . 0 26.2 
2 9 .0 26.4 
27.2 25. 9 
2 1J. . . 1 . 0 
\>J 
\..'l 
Plate No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
1, 
........... 
12 
13 
14 
15 
1·1ean Dia:net er 
Standar d Deviation 
p < 0 .. 1 > 0.05 
TABLE VII 
In Vitro Inhibition of Ps~ aeruginosa By Dry 
Foam and Ointment Containing 0.1% Gentan:.icin 
Diameter, Zone of Inhibition(mm) 
0 .1% Gentamicin 
Dry Foam 
11.0 
11. '-i-
13.0 
13.5 
10.8 
10 .2 
10 . 0 
13.6 
1'+. LJ-
]_lj. . 6 
12 . 8 
12 . 6 
12.0 
12 .. 0 
12 ~ 0 
12 . 3 
1. '+ 
0 .1?6 Gent a:ni cin 
Ointment 
15.2 
13.0 
12 . 0 
14.6 
14 .6 
12.6 
11.0 
1L~.s 
15.5 
15.2 
13.2 
11.0 
13.6 
1.6 
\.}J 
-!==-
TABLE VIII 
Summary of In Vitro Hicrobiological Evaluation of Nedicated Dry Foams and Ointments 
Formul ation 
0.5% Silver Nitrate Dry Foam 
0 .5% Silver Nitr ate Ointment 
1% Ag Sulfadia zine Dry Foam 
1% Ag Sulfadiazine Ointment 
2% Ag Sulfadiazine Dry Foam 
2% Ag Sulfadiazine Ointment 
3% Ag Sulfadiazine Dry Foam 
3% Ag Sulfadiazine Ointment 
8 . 5% Mafeni de Dry Foam 
8 . 5% Mafenide Ointment 
0. 1% Gentamicin Dry Foam 
0.1% Gentamicin Ointmentb 
0.2% Nitrofurazone Dry Foamc 
0 . 2% Nitrofurazone OintmentC 
Dry Foam Controlc 
Neobase Ointment Contro1c 
Mea..."'l Diameter, a 
Zone of Inhibition(mm2 
12.8 
9.3 
17.2 
8 .5 
16.6 
9 . 7 
20.6 
9.7 
27.2 
25.9 
12.3 
13 . 6 
.:1 - Results listed are aver age val ues for fifteen determinations . 
b - Gentamicin Ointment liquef'icrl ut t ho incubation t emperG.ture . 
c - No zones of inhibition observed. 
Standard 
Deviation Stu.d.ent t 
1.6 p < 0 . 001 
1 .. 2 
1.7 p < 0 . 001 
1.1 
2.1 p < 0.001 
0 . 9 
1.7 p < 0.001 
1.1 
2 . 4- p < 0.1 > 0 .05 
1.0 
1..4- p < 0 . 1 > 0 . 05 
1 . 6 
\.N 
\}1 
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study, as they appear ed to be representative of the tvTO 
types of in vitro data obtained . These two formulations 
. 0 0 0 0 
'l'lere subJected to storage at -·5 , 5 , 25 , and LJ-5 • In 
order to determine t h e effect of var ying levels of humidity at 
these temperatures, the medicated dry foams were stored in 
three different humidity situations , namely, dry, ambient, 
and saturated. A dry environment \.Jas created by placing the 
dry foams into open one-half ounce ointment jars , and placing 
these into tightly sealed two ounce ointment j ars containing 
0.5 g. of the dessicant, calcium sulfate.a An ambient humidity 
environment was provided by placing the o.ry foams int o si~:i.lar 
containers ,.,i t hout dessicant . A \'Jater saturated condition 
· wa.s created by pl acing t he dry foams into ouen one-ha l f ounce 
ointment jars and placing these into tightly sealed tvm ounce 
ointment jars containing approximately 20 ml . of vmter. Gross 
Dhysical ~ruination of the samples was made daily to deter-
mine the effect of storage upon stability. The results ~f 
this ·study are listed in Table IX. 
As the ingredients of the dry foam formulations are 
freely water soluble, it was asswned that storage in a tight, 
light-resistant container," such as an ointment jar, would 
prevent or minimize any adverse effects that moisture may 
have upon the formulations. However, as liquefaction occurred 
vJith a ll but two of the samples t ested, it was a ssumed that an 
ointment jar, although a tight container, does not prevent 
a - Drierite, Vl. A. Hammond Drierit e Co., Zenia, Ohio .. 
passage of moisture. In addition, the a d.visability of 
maintaining 10% moisture in the dry foam was determined 
during the formulation of various experimental dry foams . 
Since loss of this moisture vJOuld result in an undesirable 
preparation, further stability studies were indicated to 
determine the extent of moisture loss from the dry foam at 
elevated temperatures. 
A second attempt \o<las made to d:evise optimum packagil:g 
a nd sto~age conditions utiliz.ing sealable , moisture- proof, 
p l astic bags.a In this studys mafenide and silver sulfa-
diazine dry foams were stored in individual bags a t -5°, 
5°, 25° , 35°, and LJ-5° at a mbient humidity. The results of 
this study are listed in Table X. 
In Vivo Eva luation 
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In order to d.evelop suitable in vi V.Q t ecb..niques , s even 
male, albino guinea pigs \'Jere subjected to various bu.rni q; 
and treatment techniques . Based upon this prelimir..a::'7 -..-·:J::-k, 
a burning procedure was devised utilizing steam projec~e~ 
through an orifice approximately 8 mm. in diameter. The 
backs of the a nimals -v1ere clipped with a hair clipper a..~O. 
shaved with an electric shaver under l ight ether anethesia . 
Each animal v..ras then \veighE.d. Appoximat el y 24 hours aft er 
shaving, four burns -vrere inflicted upon the back of each 
animal while under ether anesthesia. Steam at a temperature 
of 80° to 90° vms directed onto the backs of the a nimals for 
a - Ziploc Bags, Dov.,r Chemical Co .. , 11Iidland, ~1ich. 
TABLE IX 
Shelf Life of Medi cated Dry Foams During Storage in Ointment Jars 
2% Sil -_rer Sulfadiazine Dry Foam B--:-5-Sb Nafen~Cie Dry-7oam 
Temp I Storage Environmenta 
(°C) Dry Ambient S~.turated Dry Amb i en-G Saturated 
- 5 
5 
25 
45 
60+0 
60+ 
14 
2 
14 
21 
2 
2 
1 
1 
1 
1 
30 
21 
2 
2 
14 
14 
2 
2 
1 
1 
1 
1 
a - Samples of each formulation wer e placed into ointment jars and stored in the dark 
at the temperatures and environments indicated. 
b - Shelf life in days as determined by gross physical examination. 
\}>; 
co 
TABLE X 
Subjective Evaluation of Medicated Dry Foam After Storage in Plastic Bags 
Storage Temperaturea Formulationb 
(°C) 2% Ag Sul~adiazine Dry Foam 8.5% Mafenide Dry Foam 
-5 
5 
25 
35 
45 
Liquefaction after 4 weeks 
Integrity retained after 4 
months 
Integrity retained after L~ 
months 
Loss of moisture, loss of 
flexibility after 1 week 
Loss of moisture, loss of 
flexibility after 1 week 
Liquefaction after 
four \•reeks 
Int egrity retained 
after LJ- months 
Liquefaction after 
8 weeks 
Loss of moisture, loss 
of flexibility, color 
change after l week · 
Loss of moisture, loss 
of flexibility , color 
change after l week 
a - Sa."llples of each formulation vJ€lre placed int o sealable~ moisture- proof plastic bags 
and stored in a dark environment at the temperatures indicated, at ambient humidity. 
b - Each formulation was inspoc-t od at \-Je c~kly intervals for 4 months . 
\.,'\l 
,_o 
L~O 
a period of ten seconds in orc1er t o obta i n :four full thickness 
injuries, each approximately 8 mm. in diameter. The animals 
\rJ er e then returned to indi vidua l cages with ample food and 
\'lat er and ob served for 24· hours. After this period of time, 
each burn was inoculated by S\•Jabbing \vith an overnight broth 
culture of Ps . aeruginosa. Therapy \r.JaS initiated 30 minutes 
after infecting the burns and repeated every tHelve hours 
thereafter. Prior to the application of the dosage for~ 
under investigation, the backs of the animals Ne:re moistened 
by the use of a nebulizer containing deionized water to 
facilitate adherence of the dosage form to the vi01Ll1d . In 
addition , cultures of the burns v-Tere obtained with stcrilG 
swabs moistened \'lith sterile water at these time intervals 
to detect the presence of Ps •. aer uginO ?.§:.• Demonstration of 
the appl :Leation and liquefaction of the medicated dry foa:1 
is illustrated in Plate I . 
As mixed colonies v1ere cultured from the burn c.:r-ec.s, 
appropriate identification tests \•Jere performed in c~C..e:: to 
distinguish Pseudomonas from other bacteria. Initial 
differentiation was made by the use of the Gram stain, since 
PseudoiB.smas is a Gram-negati,ve bacteria (L~5). Secondly, the 
ability of Pseudomonas species to produce a diffusible blue-
green pigment, pyocyanin, a l s o a ided in the identification 
procedures (46). In addition most strains el aborate another 
pigment knovm as pyoverdin or fluorescein (45-4·7). According 
to Ward et al (48), f luoresc ein produces fluorescence upon 
exposure to ultraviol Gt light even in the presence of other 
bacteria. This fluorescence has been used in the clinical 
diagnosis of the onset of Pseudomonas burn sepsis. For this 
a 
reason, a short vmvelength ultraviolet lamp was used as an 
aid in identifying and quantifying Ps._ aeruginosa. isolated 
from the guinea pig burn areas. Demonstration of the fluo-
rescence of Ps* aeruginosa can be seen in Plates II-IV. 
Once isolation and identification of the Gram-negat ive 
bacteria were accomplished, visual examination permitted the 
differentiation of three types of bacteria, namely, flu ores·-
cent, diffusible, pigment-producing colonies; ivory-colored 
colonies; and yellov1-orange colonies. Further identifica-
tion tests were performed on representative samples of these 
three Gram-negative bacteria in oro.er to substantiate the 
identification. Identification of Ps .. aerug-inosa can be 
accomplished by the u~;e of several biochemical tests (49--51) .. 
Of tbes~, test s_tor oxidase, and indole, were selected to 
differentiate the test organism from the other Gram-~e€ative 
bacteria isolated from the animal burns8 
1. Test For Oxidase 
Patho Tee - COb test papers were used 
to detect the presence of cytochrome 
oxidase. Usi~g a platinum loop smear 
some of the suspected colony across the 
moistened test paper. The presence of 
oxidase is indicated by the appearance 
of a blue color. 
a - I1inera light, Ultra-Violet Products, Inc .. , San Gabriel, Ca. 
b - Available from General Diagnostics Division, Harner-
Chilcott, Morris Pl ains, N. J. 
Appearance of Burn on 
Guinea Pig 2L~ Hours 
After Injury 
Ee.rly Stages of Lique-
faction (Time = ·5 sec) 
· Placement of Medicated 
Dry Foam onto Burn Area 
(Time = 0) 
Complet e Liquefaction 
(Time = 10 sec) 
L 
Plate I . Application and Liquefaction oi' 
f1edicated Dry Foam In Vivo 
4-4 
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Plate I I . Fluorescence of Ps. aeruginosa In Vivo 
Legend: I = Culture From Infected Untreated Burn 
U = Culture From Uninfected Untreated Burn 
OB = Culture From Infected Burn Treated With 8.5% Mafenide Ointment 
FB = Culture From Infected Burn Treated With 8.5% Mafenide Dry Foam 
Fluorescent Light Source Ultraviolet Light Source 
\'lith Yellow Filter. Note 
Fluorescence in I. Use of 
Yellow Filter Facilitates 
Visualization. 
Ultraviolet Light Source. 
Note Fluorescence in I • . 
Blue Light Source Prevents 
Optimal Visualization. 
Plate III . Fluorescence of Ps . aeruginosa Cultured From In Vivo Maf enide 
St udy at 108 Hours 
.;:=-
--..:3 
Fluorescent Light Source Ultrav~olet Light Source 
With Yt llow Filter; Note 
Fluore~cence Along Upper 
Edge o~ Eschar • . Use of 
Yellow! Filter Facilitates 
Visualization. 
Ultraviolet Light Source; 
Note Fluorescence Along 
Upper Edge of Eschar. Blue 
Light Source Prevents 
Optimal Visualization. 
Plate IV. Fluorescence of Ps . aerug;nosa on Nine Day Old Eschar -t:-\..0 
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2. Test For Indole 
Kovac's Reagent 
Paradimethylaminobenzaldehyde 5 g. 
Isoamyl alcohol • • • • • • • 75 ml. 
Concentrated Hydrochloric Acid 25 m1 . 
Dissolve the aldehyde in the alcohol by gentle 
Harming in a 500 vJater bath. Cool and a.dd tbe 
acid .. . Store in a dark bottle at 40. Ad.d 0 . 5 
ml. of Kovac's Reagent to a 1-2 day peptone 
water culture. A posi ti v·e reaction for the 
presence of indole is indicated by the presence 
of a pink color. 
The results of the identification tests are listed in 
Table XI. 
In Vivo Evaluation - ~1afenide 
As tbe in vitro studies \•lith mafenide produced the 
largest zones of inhibition, in vivo evaluation of the dry 
foam and ointment \vas performed utiliz'ting this therapeut i c 
agent. In order t o compare the effectivenBss of the dry 
foam containing 8 . 5% mafenide \'lith the correspond...ins oint-
ment, fi fteen male guinea pigs, each weighing approrima-::-ely 
300 g .. v.rere randomly selected for study , after keepin.s -:;nem 
i n individual cages for at least one week. During the course 
of the study each animal vms provided with ample food and 
wat er.. Each animal \•!as shaved, weigb.ed , and burned i n the 
manner previously described. Tv;enty-four hours after burn-
ing , three of the burns were inoculated by S\vabbing with an 
overnight broth cul ture of Ps. aeruginosa, \·Thile the fourth 
area on each ani mal served as the burned, uninfected control. 
Of the three infected areas , one was medicated with 0 .1 g. of 
the mafenide ointment appl ied by means of a tongue depressor . 
TABLE XI 
Results of Microbiological Identi f i cation Test s 
IdentiJI~c-ati on-'1' est 
Organisma Gram Stain Indole GAi dase Fluorb Pigmentc 
Ps .. a.eruginosa, A.T.c.c. 9721 
- - + + + 
Unknovm (fluorescent) - - + + + 
Unknovm (ivory) 
- + 
Un.."k:no,·m (yellow) 
a - Unkno~m organisms were isolated from burn wounds during in vivo studies . 
Representative samples of these were subjected to the tests indicated. 
b - Fluorescence was observed using ultraviolet light. 
c - Production of a diffusible . pigment indicates a. positive result. 
\.Ji 
f-J 
The ~econd area was medicated with the mafenide dry foam, 
applied in the form of 2.5 cm.2 • The third area served as 
the burned infected control. Swab cultures I•Tere obtained 
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and therapy vJas continued every twelve hours for 156 hours 
(6 l/2 days). Positive cultures v1ere considered to be those 
in Nhich five or more colonies of the test organism were 
isolated and identified. · The results of this study are 
listed in Tables XII and XIII and are illustrated in Fi gure 1 .. 
In Vivo hvaluation - Silver Sulfadiazin~ 
Of the three concentrations of silver sulfadiazine oi nt-
ment tested by the in vit ro methods , the 2% preparation appeared 
to be the optimal concentration. Because of this, the relative 
in vivo effectiveness of the dry foam as a topical dosage form 
in comparison to the ointment was determined using this ther s. -
peutic concentration. Fifteen male guinea pigs, each weighing 
approximately 400 g., \vere randomly selected for study ., after 
keeping them in individual cages for at least one week~ Each 
animal was provided v1ith ample food and water during t he course 
of the study. Each animal -vms shaved and burned in t he pre-· 
viously described manner.. Each of the four burn areas '\<:a s 
incoulated by mmbbing \•lith an overnight broth culture of the 
test organism and assigned therapeutic regimes as .follov!S: 
0.1 g. of 2% silver sulfadiazine in Neobase Ointment; 2.5 cm. 2 
of 2% silver sulfadiazine clry foam; 0.1 g. of the Neobase 
Ointment as the control; and 2.5 cm. 2 of the non-medicated 
dry foam as a control.. This therapy was continued every 
twelve hours for 72 hours. In addition, swab cultures were 
~ABLE XII 
Mafenide Therapy of Burned Guinea Pigs at 156 Hours 
I 
No. of Pdeudcrnonas Coloniesb After Treatmentc With 
Mafenide I'1afenide Uninf Inf 
Animal Numbera Dry Foam Ointment Control Control 
1 ad 0 +++ + 
2 0 0 0 +++ 
3 0 0 0 +++ 
4 0 I 0 0 +++ 
5 0 0 0 + 
6 0 0 0 +++ 
7 0 0 + +++ 
8 0 0 0 
9 0 0 0 +++ 
10 0 0 ++ +++ 
11 0 0 0 + ++ 
12 0 0 0 +++ 
13 0 0 +++ +++ \Jl 
\ .)-J 
TABLE XII (continued) 
No . of Pseudomonas Coloniesb After Treatmentc 1•1/ith 
Animal Nurnbera 
Mafenide Nafenide Uninf . Inf. 
Dry Foam Ointment Control Control 
14 0 0 +++ +++ 
15 0 0 +++ +++ 
Total 0 I 0 6 15 
a - Each of fift een animals rec eived four full thickness burns . Three of the four 
burns per animal were inoculated \vith an overnight culture of Ps . aeruginosa. 
b - Cultures of each burn were obtained every 12 hours for 156 hours "~:lith sterile 
swabs moistened with sterile water. Plat ing and incubating of the cultures 
were followeo. by isolation and identification of the bacteria . 
c - Treatment consisted of 8.5% Mafenide Ointment or Dry Foam , applied to the 
involved site every twelve hours ffor 156 hours . In addition, one burn per 
animal served as the uninfected , untreat ed control, and one served as the 
infected, untreated control. 
d - Code: 0 = 
+ = 
++ = 
+++ = 
0- 4 Pseudomonas colonies isolated and i dentifi ed from each burn. 
5- 10 Pseudomonas colonie s isolated and identified from each burn., 
11- 20 Pseudomonns colonies isolated and identified from each burn . 
21 or more faourioinonas colonies isolated and identified f rom each burn. 
\Ji 
.;:: 
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TABLE XIII 
Results of Mafenide Therapy of Burned Guinea Pigs 
Number of Anima1sb \vith Positive d 
Pseudomonas Culturesc After Treatment With 
r1afenide Maf enide 
(hr )~-~-- _ Dry Foam 
Uninf. 
Ointment Control 
12 14 4 2 
24 1 l 5 
36 0 0 6 
L~8 0 0 5 
60 0 0 8 
?2 0 0 8 
84 0 0 8 
96 0 0 10 
108 
I 
0 0 5 
120 0 0 8 
132 0 0 8 
Inf. 
Control 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
\.i1 
\.,,'1 
. a Ti me 
TABLE XIII (continued) 
Number of Animalsb \'lith Positive d 
Pseudomonas Cult uresc After Treatment With 
I"lafenide Uninf. Inf. 
(hr) Dry Foam 
Hafenide 
Ointment Control Control 
144 
156 
0 
0 
0 
0 
8 
6 
15 
15 
a - Times listed are .the hours after inoculation 'tiith an overnight broth culture of 
Ps. aeruginosa. 
b - Each of fifteen animals received four full thickness burns. 
c - A positive culture was considered to be one in which five or more Ps. aeruginosa 
colonies were isolated and identified from a burn . 
d - Treatment consisted of 8.5% Mafeni~e Ointment or Dry Foam, applied to the 
involved site every twelve hours fpr 156 hours . In addition, one burn per 
animal served as the uninf8ct ed untreat ed control and one burn per animal 
served as the infected untreated cont~ol. 
\ ) 1 
C'l 
15 . - - - - -- --- - - - - - - - -- - ..._ - .....  - ----
14 
13 
12 
1 
3 
2 
1 
0 
12 
24 
36 
48 
= Infecte d Untreated Control 
o--<l -· Uninfected Untreated Control 
= 8. 5% Mafenide Dry Foam 
.--e = 8. 5% ?,lafenide Ointment 
60 84 108 132 156 
72 96 120 141 
Hours Afte r Inoculating Burned Anim::o. ls 
FIGURE 1. NUMBER OF INFECTED GUINEA PJGS DURING THERl\PY 
WITH ~lA FEN I DE 
r: r-J 
_) ( 
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obtained from each burn area every t\·lelve hours in order to 
isolate and identify the t est organism. The r esults of 
this study are listed in Tables XIV and XV , and are illus-
trated in Figure 2. 
After 72 hours of treatment, a crossover study wa s 
employed to determine the effectiveness of the medicated 
formulations in the eradication of a n established burn \'WUnd 
infection. Therapy vdtb silver sulfadiazine ointment e.:r~d d.ry 
foam \1/as instituted on those ar eas previously treated v.'ith 
the nonmedicated ointment and dry foam c ontrols , r espectively. 
This regime vms continued until 156 hours after t he init i a l 
inoculation of the burn areas. The r esult s of this stud;:{ are 
listed in Tables XVI and XVII, and a r e illustrated in Fi gure 3. 
TABLE XIV 
Silver Sulfadiazine Therapy of Burned Guinea Pigs at 72 Hours 
No. of Pseudomonas Colonies0- Afte; T;.e~tm~;tc With 
A1. • 1 N ' a 
Ag Sulfadiazine Ag Sulfadiazine Dry Foam Ointment 
n1ma rumo er Dry Foam Ointment Control Control 
1 od 0 ,..!.. ' ' 'T" +++ 
2 0 +++ +-'--1.. +++ 
3 0 0 + +++ 
4 0 0 + +++ 
5 0 0 ++ +++ 
6 0 + ++ +++ 
7 ' -!- ++ +++ +++ 
8 0 +-t-+ + +++ 
9 0 0 ++ +++ 
10 0 0 +++ +++ 
11 0 0 +~~ 1· +++ 
12 0 0 -H ··!· -f--'--1. ' . 
13 0 +· ++ +++ Vi '-.() 
TABLE XIV (continued) 
No . of Pseudomonas Coloniesb After Treatment 0 Vlith 
Animal Numbera 
Ag Sulfadiazine I Dry Foam Ag Sulfadiazine Ointment Dry Foam Control Ointment Control 
14 0 +++ ++ +++ 
15 0 ++ +++ +++ 
Total 1* 7* 15 15 
:t-p < 0.05 > 0 . 01 
a - Each of fifteen animal s received four full thickness burns and were inoculated 
with an overni ght broth cul ture of Ps. aeruginosa. 
b - Cultures of each burn were obtained every 12 hours for 72 hours with sterile 
swabs moistened with sterile water. Plating and incubating of the cultures 
were followed by isolation and identification of the bacteria . 
c - Treatment consisted of 2% Silver Sulfadiazine Ointment, 29.6 Silver Sulfadiazine 
Dry Foam, Neobase Ointment Control, or Dry Foam Control applied to the involved 
site every tr,velve hours for 72 hours. 
d - Code : 0 = 0-4 colonies; + = 5-10 colonies; ++ = 11-20 colonies; +++ = 21 or 
more colonies; iso1nt;cc1 and identified. from each burn as Ps .. a8ruginosa. 
0': 
0 
TABLE "XV 
Results of Silver Sulfadiazine Therapy of Burned Guinea Pigs 
m · a 
.J.lme 
(hr) 
12 
24 
36 
48 
60 
72 
*P < 0.05 ) 0.01 
Numb er of Animals0 With Positive 
Pseudomonas Cult uresc After Treatmentd With 
Ag Sul fadi azine I Ag Sul fadiazi ne Dry Foam 
Dry Foam Ointment Contr ol 
14 13 15 
8 10 15 
1 9 14 
1 6 15 
1 7 15 
1* I 7* 15 I 
I 
Ointment 
Control 
15 
15 
15 
15 
15 
15 
a - Times listed are the hours after inoculation with an overnight broth culture of 
Ps . aeruginosa . 
b - Each of fift een animals roc0-i.ved four full t hiclm ess burns. 
c - A positive culture was co'il n :i.<1cJ.'cd. to be one in '\vhich five or more Ps . aeruginosa 
colonies were isolated and identifi ed fr·om a burn. 
d - Treatment consisted of 2% Silver Sulfadiazine Ointment, 2% Silver Sulfadiazine 
Dr y Foam, Neobase Ointment Control, or Dry Foam Cont rol appl ied to the involved 
site ever y t\vel ve hours f or 72 hours .. 
m 
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4 
3 
2 
1 
o · 
- - - = Dry Foam Contr.ol 
e---o - Ointment Control 
62 
---::: 2% Ag Su lfadiazine Dry roam 
o--o = 2% Ag Sulfadiazine Ointment 
Hours After Inoculating Burned Animals 
FIGURE 2. NlThlBER OF INFECTED GUINEA PIGS DU11ING 
THERAPY WJTJ-I SILVER SULFADIAZINE 
T!ABLE XVI 
Crossover Silver Sulfadiazine Thbrapy of Burned Guinea Pigs at 156 Hours 
No . of Pbeudo~onas Coloniesb After Treatmentc With 
Animal Numbera 
Dry Foam/Ag Se1fadiazine Ointment/~g Sulfadiazine 
Dry F,oam OJ.ntment 
1 odl 0 
2 0 0 
3 0 0 
4 0 0 
5 0 0 
6 0 +++ 
7 +++ +++ 
8 0 0 
9 0 0 
10 +++ 0 
11 ++-1- 0 
12 0 +-I-
13 0 0 ()I \_,'-) 
Animal Numbera 
14 
15 
Total 
*P = 0.1 
TABLE XVI (continued) 
No . of Pseudomonas Coloniesb After Treatmentc With 
Dry Foam/Ag Sulfadiazine 
Dry Foam 
+++ 
0 
4>!< 
Ointment/Ag Sulfadiazine 
Ointment 
+++ 
+ ++ 
5* 
a - Each of fifteen animals received four full thickness burns and were inoculated 
with an overnight; cult ure of Ps. a?ruginosa. 
b - Cultures of each burn 'ttlere obtained every t welve hours for 156 hours with sterile 
swabs moistened with sterile water. Plating and incubating of the cultures were 
follo.,.Jed by isolation and identification of Ps .. aeruginosa. 
c - Treatment consisted of the appli cation of Dry Foam or Ointment Controls to the 
involved sites every t welve hours for 72 hours . This \•las followed. by application 
of 2% Silver Sulfadiazine Ointment or 2% Silver Sulfadiazine Dry Foam every 
twelve hours for 72 hours. 
d - Code : 0 = 
+ = 
++ = 
+++ = 
0-4 Colonies if:iole:l:od and identified from each burn 
5-10 Colon:lcn ieolatcd -and identified from each ~urn 
11- 20 Coloni n.a l.oolo.teo. :J.nd identified f r om each burn 
21 or more colonien ioolnted and identified from each burn. 
a-. 
-...-
m · a I J.me 
TJABLE XVII 
Results of Crossover Silver Sultadiazine Therapy of Burned Guinea Pigs 
I Number of Animalsb With Positi ve 
Pseuaomonas Culturesc After Treatmentd 1ilith 
Dry Foam/Ag Sul fadiazine [br)~-- Dry Fbam Ointment/Ag Sulfadiazine Ointment 
12 
24 
36 
48 
60 
72 
84 
96 
108 
120 
132 
15 
15 
14 
15 
15 
15 
13 
10 
7 
8 
6 
15 
15 
15 
15 
15 
15 
15 
12 
11 
8 
7 
m 
V1 
m. a :.nme 
TABLE XVII (continued) 
Number of Animalsb Wi th Positived 
Pseudomonas Culturesc After Treatment With 
Dry Foam/Ag Sulfadiazine 
(hr)~-~ Dry Foam 
Ointment/Ag Sulfadiazine 
Ointment 
lLJ-4. 4 5 
156 4* 5* 
*P = 0.1 
a - Times listed are the hours after inoculat ion with an overnight broth culture of 
Ps. aeruginosa . 
b - Each of fifteen animals received four full t hickness burns. 
c - A positive culture 1tJaS considered to be one in \·Jhich five or more Ps. aeruginosa 
colonies \-.rer e isolated and identified from a burn. 
d - Treatment consisted of Dry Foam Control or Neoba se Ointment Control applied to 
the involved s ites every b·mlve hours for 72 hours.. This therapy vras f ollm•Ied 
by the application of 2% Silver Sulfadiazine Dry Foam or 2% Silver Sulfadiazine 
Ointment to the involved sites every twelve hours for 72 hours. 
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FIGURE 3 . N1J!,mER OF INFECTED GUINEA PIGS DUR lNG CROSSOVER 
THERAPY WJ TH SILVER SULFADIAZINE 
DISCUSSION 
In treating the massively burned patient, the physician 
has available several alternatives 1-vith respect to local 
therapye Frequently, medicated ointments are selected as 
the vehicle for appiication of therapeutic agent s useful in 
preventing and treating microbial proliferation.. Alt houe;h 
treatment based upon the application of medicat ed semi-
solids has proven to be an effective therapeutic approach, 
one must be concerned with patient comfort during appl icat ion. 
Ointments must be manually spread onto the involved sites 
resulting in a painful experience for the patient. The pos si-· 
ble pain upon application may lead to a lack of patient 
acceptance of this therapeutic technique, i n addit i on to com-
plicating the already stressful situation. li'urther, removal 
of ointments to facilitate visual examinat i on of t he :.es:!.ons 
is difficult due to the limited water solubility of most 
components of this dosage form. 
A second approach to local therapy includes the use of 
various types of dressings .. Occlusive dressings provide 
both absorptive and protective functions upon application 
to burns. In addition, occlusive gauze dressings impregnated 
\vith medicated s emisolids '\.vill provide a suitable therapeutic 
effect. HO\vever, optimal drainage from the burn must occur 
in order to prevent maceration of the advancing edge of 
ep:i.thelial grov1th. If proper drainage does not occur, the 
increas e in maceration may r esult in a higher incidence of 
infection and a a.ecrease in tissue regeneration. Further, 
gauze dressings adhere to the v10und and produce pain and 
tissue loss upon removal. 
In addition t o the use of dressings containing semi-
sol ids , gauze dressings medicated with 0.5% silver nitrate 
can be selected as <;ill alternate local therapeutic measuT-e . 
This method requires the application of the solution e\-ery 
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t\·:o hours in order to i nsure adequate solution levels 0 :1 the 
skin. The need to keep dressings saturated with the medicat ed 
solution Hill r esult in increased nursing time per pati ent , 
and, therefore, has been considered to be a disadvantage, 
along \~Jith the other dise.dvantages of staining , v.retness and 
coldness, and body el ectrolyte effects , previously described. 
Due to the potential disadvantages associated Hi t h t he 
current practices of local therapy for ~he severely -burned 
patient, an improved method of local treatment v1as dev i sed. 
I n order to eliminate the need t o spread a medicate~ 2¥; li-
cation manually onto the .burn, and to overcome the proslems 
associated with the removal of medicated applications, a 
hydrophilic foam \vas formul~ted. Traditionally, a pres-
surized aerosol is used t o generate a medicated foam at the 
time of application. However, an aerosol i'ormulation v1as 
not sel ected for this vTOrk due t o the potentially harmful 
effect that may be associated with the applicat ion of pro-
pellants, s olvents , and other similar aerosol auxiliary agents 
t o denuded areas. Rather, the hydrophilic foam was generated 
(0 
by whippinr; and casting an a erated film, dried to a uniform 
moisture content of 10%. Once dried, the dry .foam appearerl. 
as a light, flexible, aerated film. Because of the r apid 
water solubility of the components of the formulation, 
application and subsequent liquefaction may be easily accom-
plished merely by placing the dry foam onto appropriate moist 
surfaces. It \!las determined that 2. 5 em .. 2 of the dry foam 
liquefies in 0.1 ml. of water at ambient temperature in 20 
seconds. In order to facilitate liquefaction, a fine 3ist 
of "mter '\'as directed onto the burn lesions prior to each 
application. A similar technique can be indicated in clini-
cal use. However, future clinical studies may demonstrate 
that application immediately after soaking a patient :Ln the 
Hubbard tank could provide sufficient moisture to insure 
liquefaction, or inherent surface moisture present on the 
lesi ons may prove to be adequate for liquefaction. 
Stability 
Preliminary stability studies \'Jere performed in c::·d.er 
to evaluate the dry foam on the basis of tackiness, flex:. -
bility, and general appearance after storage at various 
tempera.tureso In conjunction \llith this, the effect of var;/-
ing levels of humidity during storage was dBtermined (see 
Tables IX and X). 
Initial design of studies t o determine the effect of 
temperature and humidity upon mafenide and silver sulfadiazine 
dry foams utilized ointment jars as tight, light-resistant 
containers. 0 0 . 0 0 Samples were stored at -5 , 5 , 25 , and 45 • 
However, as liquefaction occurred with'ten of t he twelve 
samples , it was assumed that an ointment jar, although a 
tight container, does not prevent passage of moisture. 
71 
Although the ointment j ars did not provide the pro~ec-
tion from moisture that vlas deemed essential for optimal 
shelf life stability, several observations v.1ere made.. J.~iq_ue-
faction of the medicateQ. dry f oams storeo. in a saturat ed 
environment was noted in l ess than 24 hours at all storage 
temperatures. It was observed that storage at 45° not only· 
resulted in liquefaction but also a color change f or the 
mafenide preparations. It appeared that t he silver sulfa-
diazine dry foam could \A!ithstand the effects of temperGture 
and humidity for longer periods of time the..1: could the mafenide 
dry foam. 
As liquefaction was noted· for all samples \vithln tv:o 
months storage, it was assumed that an alternate me~~s cf 
storage vms necessary. For this reason, sealabl e, mois":Clre-
proof plastic bags were selected as protective containers for 
the medicated dry foams. In this second stability study , 
mafenide and silver sulfadi~zine dry foams v7ere stored for 
o o · o o four months in individual Ziploc Bags at -5 , 5 , 25 , 35 , 
and 45° in a dark environment. 
After storage for four months, no change in appearance 
''ms noted for the dry foams stored at 5°. Those stored at - 5° 
liquefied after four v~eeks storage . Ho\·rever, the silver sulfa-
diazine stored at 25° retained its integrity throughout the 
?2 
study, v.1hi l e the mafenide dry foam stored at this temperature 
liquefied within two months. Storage in an oven at elevat ed 
temperatures resulted in excessive moisture loss and loss of 
flexibility. With respect to the mafenide dry foam, a color 
change "!as noted d.uring storage at elevated temperatures. 
As a re sult of the data obtained from the stability 
studies, several recommendations can be made. The effect of 
moisture is obvious, and therefore, future package design 
should include the use of plastics or other suitable materials 
that are impervious to moisture. It should be noted that the 
plastic bags used in this study, although described as "moisture-
proof, " do not prevent passage of moisture. The pre~; sure seal, 
or Ziploc, for these bags do not provide a completely tight 
seal, and. therefore , do not serve as a totally \'Jater-impervious 
container. 
--'rhe adverse effect of elevated temperatures upon-the 
stability of the dry i:'oams Has noted in these studies.. Storage 
of the ·formulations at 45°, resulted in a loss of pl~st~~ity 
within one \'Jeek due to the evaporation of moisture from the 
dry foam. This sensitivity of the formulations to high tem--
peratures may necessitate storage o.t refrigerated conditions 
in order to insure adequate shelf life. 
In Vitro Re sults 
In order to determine the effectiveness of the dry foam 
as a dosage form, a modified agar diffusion test was performed 
utilizing Ps. aeruginosa as the test organism. Mafenide, 
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silver sulfadiazine, silver nitrate, gentamicin, and 
nit rofurazone \:Jere sel ected as typical topical antibacterials 
for study since t hese agents are frequently indicated in 
l ocal burn therapy. The diameters of the zones of inhibition 
observed vdth the medicated dry f oam formulations V·Tere com-
pared with those of the corresponding medicat ed ointments 
( see Table VIII). 
Hafenide , 8 .. 5%, was tested in vitro as the dry f oa::-:1 and 
also as the commercially available ointment. The mean dia-
meter for 15 replicate determinat ions using mafenide <iry f oam 
mea sur ed 27 .. 2 mm., \•Jbile s imi l ar testing of the ointment fo:rmu-4 
lations produced zones equal t o 25.9 mrn.. In spite of the fact 
that the dry foam produced. larger zones, student t eYaluation 
of these results suggest t hat a significant dif ference may 
not exist "between the mean diameters of the zones of inhi bi -
t-ion (P < 0.1 > 0.05). For this reason, iv was assumed that 
the dry foam \vas as effective as the ointment \>Jhe:1 testing 
in vitro release of mafenide from these two dosage fcr~s . 
Due to the r ecent i nter est in silver sulfadiazine in 
local burn therapy, in vitro tests \'Jere performed even though 
this agent has not r eceived _final Food and Drug Administration 
approval. Hi th no ·product of silver sulfadiazine commerci ally· 
avail able, N eo base Ointment \llas selected a s t he ointment 
vehicle to \•Jhich 1, 2, and 3% silver sulfadiazine \•Tas added. 
In addition, dry foam formulations \I/ er e prepared containing 
these concentrations . Zones of inhibition measured 17.1 mmo 
for 1% silver sulfadi azine dry foam and 8 .. 5 mm .. for the 
corresponding ointment (P < 0.001). In testing the 296 
ointment, the zones measured 9. 7 mm. , \l!hj_le the dry foam 
at this concentration produced zones of 16.6 mm . (P < 0 .. 001) . 
For the 3% concentration, the zones measured 9.'7 mm. and 
20.6 mm., respectively (P ( 0.001). Significance,. as dete:r.·· 
mined by student t evaluation, indicated that the zones of 
inhibition, and hence, release of the therapeutic agent, were 
greater for the medicated dry foam than for the cor re spcndi ::1g 
medicated ointment. 
Clinically, silver nitrate is applied topically as a 
dressing saturated v.dth 0 . 5% silver nitrate solution. now-
·ever, for this study, 0.5% silver nitrate in Neobase Oir.tment~ 
and also in the dry foam vJere prepared and evaluated in _v i t£.2. .. 
Mean diameters of the zones of inhibition measured 12.8 mm . 
and 9.3 mm . for the dry f oam and ointment preparat ions , 
respectively. As was the case vrith silver sulfadiazi~ 
the dry foam proved to be a better dosage f'orm tbc-...n t he 
corresponding ointment , as determined. b;y the subseque::t student 
t evaluation (P ( 0.001). 
In determining the in vitro effect iveness of- the dry foam 
and ointment as a vehicle for 0.1% gentamicin, liquefaction 
of the ointment occurred during incubation. Due to the lique-
faction and resultant flov.Ting of the ointment onto the seeded 
agar plates, it is possible that exagger ated fal se values 
wer e obtained. In spite of this possibility, zones were 
measured and evaluated. 1-i'or the medicated dry foam, mean 
values of 12.3 mm . were r ecorded , while values for the medicated 
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ointment measured 13.6 mm. Student t computations suggest 
no signi ficance between the means of the data obtained 
(P < 0.1 ) 0.05) . li'or this reason, it was assumed t hat t he 
dry foam and ointment v1ere equally effect i ve as dosage forms 
for gentamicin. 
Nitrofurazone has been frequently used to treat various 
infected l esions of the skin. The topical vehicl e for nitro-
. a furazone , Solubase, has been described as a vJater solutle 
dressing for use on infect ed burn lesions. Therefore , in 
order to compare this water solubl e drug product \vith t he 
dry foam, nitrofurazone \·Jas included in the in vit.E.Q_ studies . 
Hm.,rever, no zones of inhibition '!!Jere detected with either the 
0.2% dry foam or ointment. Because of this, it v;as assumed 
that nitrof urazone i s not effective against t he str ain of 
Ps..!.. aeruginosa used in this study. 
-Based upon the in v~tro agar diffusion studies, the 
relative effectiveness of the dry foam and ointment dosa~e 
forms VJas ascertained. The data indicated that r elease =·ates , 
as determined by the zones of inhibition, from the dry foam 
v1er e at l east as gr eat as that from the ointments . In the 
cas e of the silver salts , the dry foam preparations produced 
statistically l ar ger zones of inhibition than the correspond--
ing ointment prepar ations. On the other hand, mafenide a nd 
gentamicin containing dosage f orms produced equivalent zones 
of inhibition and, hence , equiva lent r a t es of release. 
a - Ava ilable from Eaton Laboratories, Division of the Norv1ich 
Pharmaca l Co .. , Norwich, N. Y. 
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In order to further evaluate the dry foam as a. dosage 
form, mafenide v-Ias subsequently sub,jected to in vivo t estinr.; .. 
f1afenide was selected for the in vivo studies because the 
in vitro data showed. that this therapeutic agent vms the mos t 
effective in vitro inhibitor of Ps. aeruginosa. Further, a s 
- ----- -
release rat es from the dry foam and ointment vJere statistica lly 
equivalent, in vivo testing was deemed necessary in order to 
further substantiate this conclusiono 
Silver sulfadiazine was also selected for in v1vo t est-
ing. The silver salts in the dry foam produced significently 
greater zones of inhibition than in the corresponding ointment~ 
Therefore, in vivo testing of silv-er sulfadia zine was indi~· 
cated in order to further determine if the d.ry .foam \._rould. 
serve as a topical dosage form of choice for t his silver s alt .. 
In Vi vo Results 
V/ith initial surface growth of Ps. aeruginos~ beir!g of 
primary concern in burn vJound sepsis, the burned, in ~"ec-'::e o. 
guinea pig was selected as the model for comparing the e ~fec­
tiveness of medicated dry foams \•lith corresponding ointments . 
As supra-eschar bacterial colonization is usually considered 
to be the first stage of local sepsis, it \!las believed that 
eradication of surface colonies would indicate the effective-
ness of the medicated dosage form. Therefore, a negative swab 
culture was selected as the parameter of effectiveness for the 
medicated preparations. 
It must be noted that other investigator s have utilized 
mortality as an indication of the effectiveness of a particular 
7'7 
local t herapeutic regime. Hov;ever, as mentioned earliei', 
variables, such as virulence of the test organism and the 
traumatic effect of the thermal injury, may adversely affect 
the mortality rates. Further, tests utilizing mortality rates 
necessitate long periods of study which may introduce a thi~·d 
variable. Specifically, the eschar, once f ormed , can lead. to 
constriction and inhibition of r espiration l eading to possibl e 
death of the animal. For this reason, long term studies may 
require the use of surgical procedures such as debriderr.ent 
and eschar removal as part of local supportive care.. I n order 
to avoid the need to develop suitable surgical techniques, 
and also to avoid the problems of virulence and trauma , mer~ 
tality r ates v.fere not used as indicat ors of effectiveness . 
Rather, the absence of the test organi sm on the surface of 
the . burn \>Jas determined in order to compare the effectiven•: ss 
of the dry foam \'Tith the corresponding ointment. 
The in vivo efficacy of the dry foam as a dosage fc~m 
was determined utilizing 8. 5% mafenide. Once sui table barn-· 
ing techniques \vere developed, it was possible to inflict four 
full thiclmess injuries of uniform size onto the dorsum of 
each animal. In this manner, the two medicat ed dosage f orms 
could be evaluated on each animal. Further, the effect of 
diffusion from one area to another was determined by util i z-
ing one burn as the infect ed, untreated control. The in vitr o 
tests produced very large zones of inhibition, and it vias 
assumed that if diffusion from a medicat ed ar ea was to oceur, 
the untreat ed infected area ,,.,ould not demonstrate the presenc e 
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of Ps. aeruginosa. However , the untreated infected areas 
gave pos itive cultures for the test organism throughout the 
study. For this r eason , it was assumed that diffusion of 
the active ingredient from one ar ea to another did not occur, 
and ther efore, did not have an inhibitory effect upon the t est 
organism . Therefore , the use of f our burn areas per animal, 
each treated v.Jith a different dosage form, appear ed to be a 
reasonabl e method of study. 
In order to determine i f cross contamination might occur 
from an infected burn to an adjacent area of no coloniz2.tion, 
the fourth burn per animal \vas not seeded. Th.is burned, unin-
fected, untreated ar ea served to demonstrate that recol oni za-
tion \<Ja s occurring throughout the study since six animals gave 
posit ive cultures at the conclusion of the study. From this 
observation, i t was a ssumed that cross contanination of tho 
other burn areas vJas occurring at a similar rate . HO\\'ever , 
as the burn ar eas treated \<lith the medicated dry foam a.r.~.d. the 
medicated ointment produced no positive cultures , it is sug-
gested that both dosage forms vmre equally effective in inhibit-
ing the grovrth of Pseudomonas in vivo. That is , both prepara-
tions er adicated s upra - eschar colonization after 36 hours of 
therapy and subsequently prevent ed the cross cont amination 
that was expected to occur due to the presence of Pseudomonas 
on the ot her burn areas . It should be not ed that both the 
in vitro and in vivo methods of study suggest that the dry 
foam and the ointment are equally effective dosage forms for 
mafenide (see Tables VI and XIII ). 
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In an attempt to demonstrate t he presence of Ps . 
aeruginosa on the burns visually, the method of \!lard (48) 
and Caplan (52) '~:Jas used. Ultraviolet light vms directed 
onto the burns to detect the charact eristic .fluorescenc e of 
Pseudomonas. Unfortunately , mafenide fluoresced with a simi-
lar intensity and color to that of fluorescein, and, tbere ~· 
fore, no differentiation could be made between t he presence 
of Pseudomonas and the presence of mafenide. Ho~o1ever, the 
untreated, infected areas produced fluoresc ence characteris-
tic of Ps. aeruginosa. Of the fifteen infect ed , untreat ed 
burns, all produced fluorescence on exposure to ultraviolet 
'light. This indirect visual demonstration of the presence 
of test organism tends to substantiate the swabbing technique 
used, f or a ll infected , untreated burns produc ed positive 
cultures for Pseudomonas. 
In addition, macroscopic examination of the burned-,-
uninfected areas under ultraviolet light prod.uced fluorescence 
\•lith five of the animals. In contrast to this , six of t hes e 
areas produced cultures positive for Pseudomonas. The dis-
cre_pancy betv~een the number of fluores cent areas and the 
number of areas with positi'!"e cultures may be explained by 
the limitation of t he ultraviolet technique. According to 
Polk et al (53), fluorescence of Pseudomonas may be observed 
~olith the naked eye as the concentration approaches and exceeds 
105 organisms per cm2 .. Evidently , the proliferation of 
Pseudomonas was not of sufficient magnitude and hence , the 
fluor escence vms not visibl e on the sixth area . 
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Once the i n vivo . test ing of mafenide dry foam and oi ntment 
substantiat ed the in vi tro data previously obtained, in vivo 
evaluation of 2% silver sulfadiazine dry foam and in Neobase 
Ointment was initiated in order to further determine t he 
advi sability of using the dry foam as a topical dosage form 
in infect ed burns. In this second study, each of fift een 
guinea pigs were inflicted ,.Jit h four ther ma l injuries . Hmv-
ever , unlike the mafenide study, all four areas vJere chall enged 
with an overnight broth culture of Ps. aer uginosa, and each 
burn v1as assigned a particular t herapeutic r egime . Thera py 
consisted of 2% silver sulfadiazine dry f oam , 2% silver sulfa-
diazine in Neobase Ointment , dry foam control, and Neobase 
Ointment control, appl ied t o the involved sit es every twe lve 
hours f or 72 hours. Svm b cultures Her e obtained. ever-:f tvlel ve 
hours , and isolation and identification of t he t est organ i sm 
\vas a ccomplished (see Table XV). 
After 72 hours of treatment, all of the unmedicateo con-
trol ar eas continued to demonstrate the presence of ths ·oac--
teria.. Of the fifteen animal burns treated wit h 2% silver 
sulfadiazine dry foam , one remained infected with Pseudomonas .. 
In contrast to this , seven of the fifteen animal burns r emained 
positive for Pseudomonas after treatment v1i th the correspond-
ing medicated ointment . Visual examination of the burns upon 
exposure to ultraviolet l ight produced .fluorescence ,.,ith all 
burns treated \vith the unmedicated d.osage forms .. The burns 
treated \·Jith 2% silver sulfadiazine dry foam failed to sho'v 
fluorescence, while two of the fifteen ani mal burns t r eat ed 
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i-Jith the medicated ointment produced fluorescence . The 
discrepancy bet\'.Teen the fluorescent identification and the 
s\..,rab culture identification Has attributed to the concen-
tration limitation of the ultraviolet technique, previously 
described. 
After 72 hours of treatment, a crossover study N'as 
initiated utilizing the burn areas previously treated with 
the unmedicatea. dosage forms (see Table XVII) . Those areas 
treated \d.th the unmedicated dry foam \v ere assigned the!'a py 
with the silver sulfadiazine dry foam , applied every tvJelve 
hours for 72 hours. In a similar manner, those areas pre-
viously treated , .. lith Neooase Ointment were assigned a treat-
ment regimen utilizing silver sulfadiazine in Neobase Oi r..tment. 
In this way, the effect of instituting therapy one-half hour 
after infecting the burns could be compared v.'ith the data 
obtained from the study instituting therapy 72 hours after 
infecting the burns. In addition, determining e.fficac:~­
utilizing crossover methods may be of value i n negatir-s 
inherent variables of the in vivo study. 
At the conclusion of the in vivo crossover study, f our 
of the animal burns treated \<rith the medicated dry foam 
remained infected, \<Jhile five of the areas treated \·'lith the 
medicated ointment r emained infected. No significance could 
be assigned to the data, as determined by Chi Square computa-
tions (P = 0 .. 1). Vlith regard to the initial study of the 
silver sulfadiazin e dosage forms, however, significance may 
exist (P ( 0.05 > 0 . 01). 
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Several factors must be considered in comparing the 
results of the initial in vivo study of the silver sulfa-
diazine dosage forms vTith that of the subsequent crossover 
study. The 72 hour delay in instituting appropriate ther apy 
may have led to antibacterial activity not s eriously aff ect ed 
by rates of release from the dosage form. The proliferat ion 
of the test organism during this initial 72 hour period prob-
ably resulted in sub-eschar colonization. This movemen~ of 
Ps. aeruginosa into tissues bel0\-7 the burn produced an envi ron-
ment for gro\lrth not easily treated with locally applied agents. 
In clinical use, local and syst ernie therapy v.rould be ind:i.cat ed 
in order to successfully combat the advanci ng bacteria. In 
addition, surgical excisi on of the devita l ized eschar v;ould 
be an abs olut e necessity in order to aid in the elimination 
of the infecting organis ms . The presence of eschar provid•3S 
an -excellent medium for bacterial growth and also provides a 
barrier between the applied drug and the sub-escha r c olcnies, 
which prevents therapeutic contact and effect. Therefor e , 
·the omission of systemic therapy and eschar removal from "t he 
cross over study may have led to the l ack of significance in 
the data. 
Therefore, from the in vivo study utilizing the s ilver 
sulfadiazine dosage forms, two s ets of dat a \•Jere obtained. 
First, v..rith therapy initiated one-half hour after inoculat i ng 
the burns, the medicated dry foam result ed in a decreased 
incidence of infection to l ess than 10%. Local t her apy with 
the corresponding medicated ointment r educed the number of 
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infected animal burns from fift een t o seven, or 46%.. This 
difference may be due t o the rapid release of silver sulfa -· 
diazine from the foam with sub sequent rapid therapeutic effect. 
Comparing these data with the results of the in vitr o determina-
tions, it appears that the dry f oam containing the silver sal ts 
is a better dosage form than the corresponding medicat ed oint-
ment. 
'rhe second s et of data to be cons idered \!Jer e those obtain ed 
using animals infected for 72 hours \·.rithout appropriate ther apy. 
As no significant difference vms noted in those animals treated 
\:Ji th the medicated dosage forms, one may conclude that t he dry 
foam i s at least as effective as the ointment . 
In evaluating the r esults of the in vit!:_'o and in vi v o 
studies, several possible c orrel ations may be made . If no 
signi.fica:1t difference can be determined fror.1 t he in vi t:::-Cl data , 
then the incidence of infection in vivo may be the s ame for both 
dosage forms. This occurred \·Ji th the mafenide studies . If , 
on the other hand, zones of inhibiti on \·Jere significant:l.;y-
greater, then the incidence of infection in vivo may also be 
greater. This assumption was demonstrated in the silver 
sulfadiazine studies. However, the effect of delaying t her apy 
in vivo may be to counteract the r apid release and r apid effect 
expected. This was demonstrated in the crossover silver s ulfa-
diazine study as equivalent incidence of infection was noted 
regardless of dosage .form used . 
SU~1MARY AND CONCLUSIONS 
The purpose of this study v.Jas to formulate a topical 
dosage form v!i th characteristics that permit appl ication. -:;o 
denuded ar eas , s uch as a burn, vlithout inunction. Selection 
of components for the formulation v1as based u pon l ack of 
toxi city a nd accepted u se in human subjects~ I n addition , 
properties such as r apid t:Jater solubility, f l ex i b i lity , e ase 
of adherence, and ease of remova l from both denuded. and intact 
areas of the skin were considered to be prime r equisites for 
the dosage form. Of s pecial importa nce \•.ras the ability of 
the formulation to demonstrate not l ess than equiva l ent 
efficacy when compared to ointment bases i n current us age . 
In order to develop a dosage form with these chare.ct eris-·· 
tics , a topical v ehi cle in the f orm of a dry f oam was fo~ffiu­
l at ed. A hydrophilic, aerated film was compounded one:_ e-v-aluated 
by the u se of in vitro and in vivo methods. In addition, p r e-
liminary stability tests \•Jere performed to insure adecuat e 
shelf life. 
The release of therapeutic agents i n vitr o from dry f oam 
formulations 1<1as compared ~t.Jith that of corresponding ointment 
bases , utilizing a modified agar diffusi on t est . Th ese s hov1ed 
t ha t s ilver nitrate a nd silver sulfadiazine produced signifi-
cantly l arger zones of inhibition \•Jhen used as the dry foam 
rather t han as an ointment. Hov.rever , mafenide and gentamicin 
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produced equivalent release rates from both the dry foam an.d 
ointment formulations . 
In vivo studies demonstrated that incidence of infection 
using the burned, infected guinea pig Has statistically equiva-
lent v1hen mafenide vms applied as either the dry foam or t he 
commercially available ointment. A therapeutic regime using 
silver sulfadiazine dry foam produced significantly better 
results than with the corresponding ointment if therapy v.'2.S 
initiated one-half hour after inoculating the animal burns. 
However, by delaying therapy for 72 hours, incidence of infec-
tion after treatment Nith either preparation was \·.rithout sig-
nificant difference. 
As a result of the in vitro and in vivo studies, it 
appears that a medicated dry foam will be value as a v ehicle 
for topical use. By eliminating the need to spread the dosage 
form onto skin lesions manually, the dry foam may prove to be 
of value in treating the seriously burned patient. Fir..ally t 
by the use of a highly water soluble topical dosage f crc, 
ease of removal may be of benefit to those involved v1ith the 
burn patient . The encouraging data obtained in this work, 
indicates that the therapeutic concept of a medicated dry foam 
has great potential, and should be subjected to clinical 
investigation at the earliest opportunity. 
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